Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease

Alena Salasova*, Giulia Monti, Olav M. Andersen and Anders Nykjaer

Abstract
The family of VPS10p-Domain (D) receptors comprises five members named SorLA, Sortilin, SorCS1, SorCS2 and SorCS3. While their physiological roles remain incompletely resolved, they have been recognized for their signaling engagements and trafficking abilities, navigating a number of molecules between endosome, Golgi compartments, and the cell surface. Strikingly, recent studies connected all the VPS10p-D receptors to Alzheimer’s disease (AD) development. In addition, they have been also associated with diseases comorbid with AD such as diabetes mellitus and major depressive disorder. This systematic review elaborates on genetic, functional, and mechanistic insights into how dysfunction in VPS10p-D receptors may contribute to AD etiology, AD onset diversity, and AD comorbidities. Starting with their functions in controlling cellular trafficking of amyloid precursor protein and the metabolism of the amyloid beta peptide, we present and exemplify how these receptors, despite being structurally similar, regulate various and distinct cellular events involved in AD. This includes a plethora of signaling crosstalks that impact on neuronal survival, neuronal wiring, neuronal polarity, and synaptic plasticity. Signaling activities of the VPS10p-D receptors are especially linked, but not limited to, the regulation of neuronal fitness and apoptosis via their physical interaction with pro- and mature neurotrophins and their receptors. By compiling the functional versatility of VPS10p-D receptors and their interactions with AD-related pathways, we aim to further propel the AD research towards VPS10p-D receptor family, knowledge that may lead to new diagnostic markers and therapeutic strategies for AD patients.

Keywords: Alzheimer’s disease, SorLA, Sortilin, SorCS1, SorCS2, SorCS3, Neurotrophins, Comorbidity

Background
Alzheimer’s disease pathophysiology
Over 55 million people worldwide suffer from dementia, which is expected to rise to 78 million by 2030 (World Alzheimer Report 2021). Alzheimer’s disease (AD) accounts for 60–80% of all diagnosed dementia cases [1]. Disturbingly, no efficient treatment is currently available. This unmet medical need is likely a consequence of the complex biology of the disease, which remains poorly understood. AD is clinically characterized by extensive neuronal cell death in the cerebral cortex and limbic system that is manifested by cognitive impairments, memory deficits, disorientation, spatiovisual difficulties, linguistic problems, and emotional imbalances. At the histopathological levels, AD is defined by the accumulation of extracellular Amyloid-β (Aβ) plaques and by the formation of intracellular neurofibrillary tangles composed of hyperphosphorylated Tau protein (pTau) in the brain parenchyma [2]. The Aβ plaques are considered the pathological hallmark of AD, but synergistic effect of pTau leading to weakening and deterioration of synapses,
dystrophic neurites, neuroinflammation, and progressive neuronal cell death is likely involved too [2, 3].

The Aβ peptide lies within the amyloid precursor protein (APP). Under normal conditions, the nascent APP is transported through the trans-Golgi network (TGN) to the plasma membrane where it is sequentially cleaved by α- and γ-secretases, respectively, disrupting the Aβ sequence. These processes produce and liberate the non-pathological, soluble fragment called sAPPα. The APP processing is depicted in (Fig. 1). According to the “amyloid cascade hypothesis”, APP may, however, escape α-secretase cleavage. Following internalization to the endosomal compartment, APP is then sequentially processed by β-secretase and γ-secretase, respectively, which generates the Aβ peptide. After secretion into the extracellular space, Aβ peptides polymerize into detrimental Aβ oligomers (AβO), later forming the ultimately insoluble, cytotoxic Aβ plaques [4]. However, attempts to treat AD by lowering Aβ have failed in several clinical trials which questions the impact of Aβ plaques as the only factor that controls disease progression [5]. Imbalance between proapoptotic and neuroprotective stimulation by proneurotrophins and mature neurotrophins likely contributes to the AD pathophysiology by negatively impacting on synaptic plasticity, and neuronal vulnerability and integrity [6–10]. Strikingly, the family of Vacuolar protein sorting 10p-Domain (VPS10p-D) receptors plays a dual role in the pathobiology of AD: it controls APP and Aβ trafficking and clearance, and it regulates the balance between the trophic and apoptotic signaling by neurotrophins such as BDNF and its precursor proBDNF. These activities may explain why members of this receptor family have surfaced as important risk genes in AD. Interestingly, the individual receptors often regulate different, sometimes even opposing aspects of AD, which will be discussed mostly in the main text.

![Fig. 1](image.png)

**Fig. 1** A simplified scheme of APP proteolytic processing and the origin of Aβ plaques. APP is a type I transmembrane receptor that contains Aβ peptide within its sequence. α-secretases such as ADAM10/17 cleave APP inside the Aβ peptide, which is disrupting, and produces soluble, secreted sAPPα fragment. sAPPα is neuroprotective, and thus this cleavage is called non-amyloidogenic pathway. The C83 peptide can be further cleaved by γ-secretase producing soluble P3 peptide. In contrast, APP can be cleaved by β-secretase, for example BACE1, creating a cytotoxic, soluble sAPPβ. The proteolysis by β-secretase exposes Aβ peptide, which is further cleaved by γ-secretase. This cleavage results in the release of Aβ monomers into the extracellular space, where they can further polymerize forming Aβ oligomers, and later Aβ plaques. This pathway is neurotoxic and is called amyloidogenic pathway.
Genetic risks in AD
The strongest genetic evidence behind AD pathogenesis is linked to familial early-onset AD (EOAD), which accounts for 5–10% of all AD cases. EOAD diagnosis has been mostly associated to autosomal-dominant mutations in three genes that result in increased levels and aggregation of Aβ. They are APP, and APP-cleaving γ-secretase presenilin components, PSEN1 and PSEN2. However, the majority of patients are diagnosed with sporadic, late-onset AD (LOAD), the heritability of which is estimated to be between 60 and 80% [11, 12]. Hence, genome-wide association studies (GWAS) investigating up to 150,000 AD cases have identified a number of risk genes underscoring the polygenic nature of LOAD [11, 13–18]. Most recently, a study incorporating more than 100,000 AD cases and almost 700,000 control individuals identified 75 risk loci, of which 42 had not previously been described [14]. Functional annotation of the risk genes indicated that amyloid aggregation, Tau phosphorylation, endocytosis, intracellular vesicle trafficking, altered lipid metabolism, and immune responses are critically involved in the pathogenesis of LOAD [2, 13–18]. Notably, around 40% of LOAD patients carry a disease-associated SNP in the gene encoding Apolipoprotein E (APOE), which exists in 3 polymorphic alleles called E2, E3, and E4. Due to such high incidence, APOE polymorphism is considered the most important genetic risk factor for LOAD [19–21]. ApoE has multiple physiological functions, but it is most known for transport of cholesterol and other lipids through the circulation system as well as within the brain parenchyma. Even though all human ApoE isoforms interact with Aβ, the functional outcome is different [22]. While ApoE2 shows neuroprotective features, ApoE4 represents the major risk factor for AD due to its involvement in Aβ processing [23]. The possession of ApoE4 allele leads to intracellular accumulation of Aβ by enhancing the uptake of Aβ peptides, resulting in the enlargement of endosomal compartments, subsequent endosomal-lysosomal pathway dysregulation, and thus decreased clearance of Aβ [24]. Several other mechanisms have been described for ApoE4 in relation to AD, including neuronal hyperactivation [25], increased Tau phosphorylation [26], modulation of neuroinflammatory pathways [23], and impaired synaptic plasticity [27]. Such abnormalities, fueled by reduced trophic support, are considered major drivers behind the progression of AD. For this reason, impairments in proteins involved in endocytic trafficking and trophic signaling have surfaced as important AD risk factors including the VPS10p-D receptors family.

AD as imbalance between neurodegeneration and neuroprotection
The neurotrophin protein family (NTs) is a subgroup of secreted neurotrophic factors that are essential for axonal outgrowth, neuronal differentiation, synaptic plasticity, and neuronal survival [9, 28, 29]. It comprises Brain-derived neurotrophic factor (BDNF), Nerve growth factor (NGF), Neurotrophin 3 (NT3), and Neurotrophin 4 (NT4); proteins that are expressed across the CNS in a spatiotemporal manner. Their actions depend on binding to transmembrane receptor complexes composed of Trpomysin receptor tyrosine kinase (Trk) that is ligand-specific, and the promiscuous neurotrophin receptor denoted p75 (p75<sup>NTR</sup>). While all neurotrophins can bind p75<sup>NTR</sup>, they show strongest binding to their respective Trk receptor: NGF binds to TrkA, BDNF and NT4 binds to TrkB, and NT3 bind to TrkC. The p75<sup>NTR</sup> can form heterodimers with a given Trk, which increases the affinity and fidelity of the Trk receptor towards its cognate neurotrophin [9].

BDNF is considered particularly relevant to AD [8, 9]. Reduced BDNF expression in the hippocampus and cortex of AD patients have been consistently reported at both transcriptional and protein levels [30–33]. In addition to its well established function in sustaining neuronal survival, BDNF is also important for cognitive abilities as it promotes learning and memory by increasing synaptic strength [8, 34, 35]. There is a naturally occurring single nucleotide polymorphism (SNP) in BDNF at codon 66, which results in the substitution of Valine with Methionine (BDNF-Val66Met). This mutation has been associated with reduced synaptic plasticity, dendritic spine elimination [36], and impaired memory and learning in AD patients [37–39]. Strikingly, in rodent and primate models of Alzheimer’s disease, BDNF gene delivery administered after disease onset showed potent neuroprotective effects by increasing synaptogenesis and synaptic plasticity leading to restoration of cognitive function [40]. Likewise, transplantation of neural stem cells have been able to rescue memory function in AD mice via BDNF-induced stimulation of synaptogenesis [41].

BDNF levels also shape the onset of AD neurodegeneration by regulating Aβ production and formation of Tau containing neuritic plaques and neurofibrillary tangles [34]. In cultured hippocampal neurons, BDNF deprivation leads to increased cell death by 50% and elevated levels of APP and PSEN1, all of which can be rescued by inhibiting Aβ production [42]. Low BDNF levels increase expression of δ-secretase that cleaves Tau to produce a pathogenic fragment [43]. Subsequently, Tau peptide becomes hyperphosphorylated, abolishing microtubule assembly, and triggering the formation of neurofibrillary...
APP phosphorylation, and enables its retrograde trafficking between TrkA and APP, which downregulates APP along the amyloidogenic pathway. NGF induces the phosphorylation of APP promoting amyloid processing of the ectodomain of p75NTR is neuroprotective against Aβ [73]. It substantially lowers amyloidogenic processing, Aβ levels, and reduces APP processing and amyloid aggregation, and protects against cognitive decline in animal models and AD patients. Indeed, regular physical activity is considered among the most efficient ways to slow AD progression today [46–49]. Taken together, the above findings suggest that increasing BDNF can have therapeutic benefits for AD patients.

NTs are synthesized as precursor proteins named “proneurotrophins” (proNTs) that undergo proteolytic cleavage of the prodomain during their maturation [50, 51]. proNTs are active signaling molecules, but as opposed to their mature counterparts, they induce apoptosis, axonal growth cone retraction, and synaptic weakening; actions that require p75NTR and are independent of Trk [50, 52–56]. As a consequence, perturbed maturation and incorrect balance between proNTs and NTs may propel the neurodegenerative process and exacerbate the disease [33, 51, 57]. Indeed, AD patients with mild to moderate cognitive impairments commonly exhibit increased levels of proBDNF in cortex, hippocampus and cerebrospinal fluid (CSF) on the expense of reduced mature BDNF [40, 57–61]. The studies showed that while proNGF is increased, NGF is decreased in the CSF and in different brain regions. Notably, this is the case in the basal forebrain where cholinergic neurons are reliant on trophic stimulation from NGF while being sensitive to proNGF-induced apoptosis [59, 62–67]. Expression of the neurotrophin receptors are altered too. Hence, p75NTR is commonly upregulated in several regions affected in AD brains [68–73], whereas TrkA [59, 74–76], TrkB [77], and TrkC [77] are downregulated. Reported changes in neurotrophin signaling components in AD patients are summarized in (Table 1).

A functional interaction between APP/Aβ metabolism and neurotrophin system has also been demonstrated. p75NTR can bind APP to enable APP trafficking to the endosomal compartment. Hence, in AD mouse models, removal of p75NTR or disruption of its internalization substantially lowers amyloidogenic processing, Aβ levels, and reduces cognitive decline [78, 79]. p75NTR also promotes amyloid-induced neuritic dystrophy [80], while soluble ectodomain of p75NTR is neuroprotective against Aβ [73]. Phosphorylation of APP promotes amyloid processing of APP along the amyloidogenic pathway. NGF induces the binding between TrkA and APP, which downregulates APP phosphorylation, and enables its retrograde trafficking into the TGN thereby bypassing β-secretase processing [81, 82]. Taken together, the imbalance between proNTs and NTs, and the expression levels of their receptors may shift their function from being neuroprotective to amplifying neurodegenerative processes.

### Table 1

| Neurotrophin    | Expression Levels in AD Patients                  |
|-----------------|--------------------------------------------------|
| **Neurotrophin**| **Upregulation**                                 |
|                 | in brain [59, 62–64];                            |
|                 | in CSF [65]                                      |
| proNGF          | Downregulation                                  |
| NGF             | in brain [68]                                    |
| proBDNF         | ↓ in brain [59, 60]                               |
| BDNF            | ↓ in brain [59, 60]                               |
| p75NTR          | ↑ in brain [68–71];                              |
|                 | ↑ in serum [72, 73]                               |
| TRKA            | ↓ in brain [59, 74–77]                            |
| TRKB            | ↓ in brain [77]                                  |
| TRKC            | ↓ in brain [77]                                  |

**Interruption to VPS10p-D receptor family**

VPS10p-D receptor family comprises five single-span type 1 transmembrane receptors SorLA, Sortilin, SorCS1, SorCS2, and SorCS3. All members of this receptor family have been recently identified as AD risk loci, and are now considered hotspots in LOAD [14, 83, 84]. Notably, SorLA has been also associated with familial EOAD [85–87]. Accordingly, based on several GWAS studies, VPS10p-D receptors exhibit key functions in the causal pathways influencing Alzheimer’s disease risk such as APP catabolic processes, cholesterol and lipid metabolism, endocytosis, cellular sorting and trafficking, and immune responses [2, 13–18]. They are involved in the etiology of a number of neurological and psychiatric disorders [88–90] including AD and frontotemporal dementia [84, 91–94]. Strikingly, genetic variants in all VPS10p-D receptors have been associated with AD, with their expression being predominantly decreased in the diseased brains. We present an overview of the structure and genetic association of the VPS10p-D receptors with AD in (Fig. 2). Except for SorCS2, the receptors functionally interact with a number of canonical AD proteins including APP, Aβ, secretases, and ApoE. We summarized the functional interactions of the receptors with AD-related proteins in (Table 2).

Expression of VPS10p-D receptors is regulated in a spatiotemporal manner from embryonic development to adulthood [119–123], with SorCS1-3 being particularly sensitive to external stimuli [124–127]. In adult brain, SorCS1-3 expression predominates in neurons, whereas Sortilin and SorLA are also expressed by immune cells such as microglia/macrophages or T and B lymphocytes.
For more insights regarding the cell-type specific expression of VPS10p-D receptors please explore e.g. Brainseq.org database. SorLA, SorCS1, and SorCS2 exist in more splice variants and cleavage products, but they can also exist in soluble forms that can modify cell signaling over long distances (so far shown for SorLA and Sortilin). These features broaden molecular interactions and signaling diversity of VPS10p-D receptors across distinct cell types [129–131]. VPS10p-D receptors act by two different signaling modalities; either they control signal transduction at the cell membrane where they bind their ligands and co-receptors, or they sort multiple types of cargoes by endocytosis and intracellular trafficking thus targeting them to distinct cellular compartments. Dysfunction in endosomal and lysosomal pathways typically causes cytotoxic protein aggregation and altered cell signaling, a major cause behind the progression of AD neurodegeneration. Importantly, VPS10p-D receptors also bind synaptic components, in particular pro- and mature neurotrophins and their respective receptors, to control
synaptic plasticity, synaptogenesis and cell fate decisions. These processes are also severely affected in AD [52, 132, 133]. The reported functional interactions between the VPS10p-D receptors, neurotrophins and their receptors are listed in (Table 3).

The VPS10p-D receptor family is named after the yeast sorting protein VPS10p-D that forms their N terminus. A schematic representation of the receptors’ structure is illustrated in (Fig. 2). All the receptors contain an extracellular propeptide typically removed by Furin-mediated cleavage in the late-Golgi compartments within the secretory pathway (Fig. 2). This proteolytic event is considered a stringent requirement for receptor activation, since it primes the VPS10p-D domain for ligand binding. So far, this has been demonstrated for SorLA and Sortilin [145–147]. The propeptide is followed by the archetype VPS10p-D domain, which is a 10-bladed β-propeller initially identified in the yeast S. cerevisiae, and that serves as binding site for many target proteins [148]. All VPS10p-D receptors can undergo ectodomain shedding to a different extend, thus releasing a soluble fragment into the extracellular space [91, 115, 149–151].

Structurally, the receptors differ from each other also by the unique sequences within their cytoplasmic domains, which determine their distinct signaling features and sorting capacities due to diverse interactions with adaptor molecules. However, given that some adaptor molecules can interact with more than one VPS10p-D receptor, and that several ligands are shared between the receptors, the VPS10p-D receptors sometimes exhibit redundant or complementary functions [133, 148]. VPS10p-D proteins can form homodimers or heterodimers with each other [152], as well as engage in formation of receptor complexes with other transmembrane proteins including APP, p75NTR, TrkA and TrkB [153].

Importantly, the receptors differ also by their preferred oligomeric states and conformational dynamics. For example, Sortilin exists only as a monomer at neutral pH, and dimerizes selectively in acidic environment [154, 155]. On the other hand, SorCS1-3 prefer forming stable dimers at neutral pH (by 79% for SorCS3) [135, 152, 156], which is likely determined by posttranslational modifications of monomers such as glycosylation levels [152]. So far three different dimeric conformations have been identified for SorCS3 [156]. Interestingly, SorLa seems to have an even preference for monomeric (by 52%) vs dimeric (by 48%) assembly at neutral pH, while the bound within the dimer is less stable [157]. Unfortunately, conformational states of SorCS1-3 and SorLA at acidic pH have not been resolved yet. Similarly, we still lack complete crystal structures of the receptors determining their intracellular tails or ligand-dependent conformational changes to obtain complex insights into their structural features.

Table 2. Reported functional interactions of VPS10p-D receptors with canonical AD-related proteins

| AD-RELATED PROTEINS | VPS10p-D RECEPTORS |
|---------------------|--------------------|
|                     | SorLA             | Sortilin          | SorCS1            | SorCS2            | SorCS3            |
| APP                 | [95–100]          | [97, 103–105]     | [106–108]         | x [101]           | x [101]           |
| Amyloid β           | [109–111]         | [93, 104, 112]    | [106, 108]        |                   |                   |
| β-secretase BACE1   | x [114]           | [97, 103, 105]    |                   |                   |                   |
| γ-secretases (PSEN1/2)| x [91, 115] | [91]             | [91, 115]         | [84, 115]         |                   |
| APOE                | x [110, 116]      | [93]             |                   |                   |                   |
| α-secretases (ADAM10, ADAM17) | x [91, 115, 117, 118] | [91] |

• - Functional interaction
x - Transcriptional changes (indirect interaction)

Table 3. Reported functional interactions of VPS10p-D receptors with components of neurotrophin signaling

| NEUROTROPHIN SIGNALING | VPS10p-D RECEPTORS |
|------------------------|--------------------|
|                       | SorLA             | Sortilin          | SorCS1            | SorCS2            | SorCS3            |
| proNGF                 | [52, 53, 134]     | [55, 132, 135]    |                   |                   |                   |
| NGF                    | x [134]           |                   |                   |                   |                   |
| proBDNF                | x [133]           |                   |                   |                   |                   |
| BDNF                   | x [137]           | [117, 138]        | [36, 54, 139]     |                   |                   |
| proNT3                 | [140, 141]        |                   |                   |                   |                   |
| p75NTR                 | [52, 53, 134]     | [55, 132]         |                   |                   |                   |
| TrkA                   | x [142]           |                   |                   |                   |                   |
| TrkB                   | [143]             |                   | [144]             | [54]             | [144]             |
| TrkC                   | [142]             |                   |                   |                   |                   |

• - Functional interaction
x - Transcriptional changes (indirect interaction)
Put together, oligomerization diversity in different subcellular compartments together with the precise composition of their protein complexes determine signaling and sorting actions of the VPS10p-D receptors which span from e.g. APP processing and Aβ turnover to cell survival and proapoptotic cell behavior. Moreover, the distinct expression profiles, various protein interactions, and high mobility of the VPS10p-D receptors highlight their pleiotropic function in neuronal trafficking and cell-to-cell communication in developing CNS as well as in adult brain [121, 122, 132]. A few studies suggested synergistic activity of these receptors, likely due to their structural similarities and overlapping ligands when expressed in the same tissue, i.e. in the hippocampus [84]. Here we present an overview of the many joint but also distinct roles played by the VPS10p-D receptors in neuronal communication, with a particular focus on their contribution to AD pathogenesis.

Main text
SorLA biology and its role in AD

The strongest genetic link to AD occurs for the SORL1 gene that has been included in the exclusive list of genes that can act as causal for AD (together with PSEN1, PSEN2, and APP [2]). Initially found in LOAD cohorts [83, 158–164], rare SORL1 variants were recently identified also in EOAD patients [85–87, 165–169], and in cases with familial AD [85, 170, 171]. Its protein product, sorting-related receptor with A-type repeats (SorLA, also known as LR11), is the largest member of the VPS10p-D receptor family. It was first identified in 1996 as a non-canonical member of the low-density lipoprotein receptor family that, in addition to the VPS10p-D, also contained 11 complement-type repeats, one EGF-type repeats, and six fibronectin type III domains [116, 172, 173]. A recent study by Zhang et al. used a single-particle cryogenic electron microscopy to determine that SorLA can exist as a monomer (52% of the particles) as well as a dimer (48% of the particles) at neutral pH. Unfortunately, the authors failed to explore conformations at acidic pH and contribution of the C-terminus to dimerization [157].

SorLA is found in most regions of the mammalian CNS with a predominant neuronal expression. It is mostly localized in endosomal sorting compartments, where it mediates the trafficking of variety of cargo molecules such as APP [95], β-secretase 1 (BACE1) [114], Aβ [109], or Glial cell line-derived neurotrophic factor (GDNF) [174]. The extensive role of SorLA in controlling protein sorting is defined by cytosolic adaptors that recognize specific motifs located within the receptor tail. Once at the cell surface, SorLA can be internalized via a clathrin-dependent mechanism through binding to the clathrin adaptor protein 2 (AP-2) [175]. Internalized SorLA molecules are trafficked from endosomal compartments either directly back to the plasma membrane, which is dependent on its interaction with retromer and SNX-27 [176, 177], or to the TGN by retrograde sorting facilitated by cytosolic adaptors PACS1 and the retromer complex containing VPS26 [177, 178]. From the TGN, SorLA can return to the endosomes by anterograde transport guided by adaptors Golgi-localized γ-ear-containing Arf-binding proteins GGA1 and GGA2 [179] and AP-1 [175]. Jointly, these trafficking events establish an endosome-TGN shuttle. Interestingly, AP-1, a key regulator of dendritic targeting of transmembrane receptors [180], was also shown to facilitate the polarized transport of SorLA towards somatodendritic domains in primary cultures of rat hippocampal neurons [181]. Recently, the heat shock protein 12A (HSP12A) was identified as an adaptable molecule able to selectively target the cytoplasmic domain of SorLA in an ATP-dependent fashion, affecting its internalization and subcellular localization [182]. Also, the last three amino acids “VIA” at the C-terminus of SorLA mediates binding to Protein Interacting with C Kinase-1 (PICK1), a protein known to promote transport of different cargos to endosomes including postsynaptic AMPA glutamate receptor (AMPAR) [183].

Recently, an alternatively spliced SORL1 variant was identified and designated “SORL1-38b” due to the inclusion of an additional exon 38b. SorLA-38b lacks four fibronectin domains, the transmembrane domain, and the cytoplasmic tail giving rise to a truncated and soluble receptor [184]. As opposed to the full-length receptor, which is enriched in the soma, SorLA-38b predominates in dendrites, suggesting it may assist synaptic functions in a manner that does not require receptor trafficking. Notably, the number of SORL1-38b transcripts is substantially decreased in the cerebellum of AD patients, whereas the expression of full-length receptor is unaltered. The protein truncation at the C-terminus disables SorLA interaction with cytosolic adaptors, which is likely involved in distinct biological processes than the full-length receptor [184].

SorLA also interacts with transmembrane receptors at the synapse such as TrkB [143], GDNF receptors GFRα1 and RET [174], and EphA4 [96] in order to modulate neuronal integrity and synaptic plasticity events. It is worth noticing that SorLA undergoes differential trafficking and polarized distribution, which subsequently influences axonal or dendritic guidance of its cargos [181]. Strikingly, SORL1 transcription can be enhanced by BDNF leading to an increased production of SorLA, which has a neuroprotective effect, and also reduces the production of Aβ levels [137]. In addition to its
intracellular functions, the ectodomain of SorLA can be liberated by ADAM17 and released into the extracellular space as soluble receptor (sSorLA) [115]. It was shown that sSorLA binds and activates EGF receptor to induce neurite outgrowth and neurite regeneration [150]. In the following paragraphs we will describe molecular interactions of SorLA with AD-related pathways and its role in neuroprotection. A schematic representation of SorLA functions is shown in (Figs. 3 and 4).

SorLA interactions in amyloidogenic cascade
While uncovering differences in gene expression between AD and control brains, Scherzer et al. discovered that SORL1 expression is dramatically reduced in hippocampus and frontal cortex of patients with sporadic AD [185, 186]. Soon after, SorLA was identified as an interaction partner for APP that determines APP intracellular trafficking and processing (Fig. 3) [95]. SorLA activity influences APP metabolism by retaining APP in the TGN, and by escorting APP out of endosomes thereby preventing proteolytic cleavages of APP into Aβ peptide in endosomal compartments [95]. SorLA also regulates polarized distribution of APP within a neuron [97, 181]. Kinetic studies from Schmidt et al. revealed that the receptor is able to inhibit oligomeric assembly of APP both in vitro and in vivo, which influences its processing as the APP dimer is a preferred substrate of its secretases [98]. These observations were confirmed using a SorLA deficient mouse line that exhibits increased production of Aβ peptides in the brain parenchyma [187]. AD mouse models APP/PSEN1 and PDAPP further revealed that cerebral levels of Aβ peptides and the deposition of plaques were significantly exacerbated in a SorLA concentration-dependent manner [187, 188]. Interestingly, overexpressed SorLA mediates an increased uptake of sAPP from the medium [97]. It is worth noticing that both, reduced levels of soluble SorLA [189] as well increased levels of soluble SorLA [190] have been detected in CSF
of AD patients. Altogether, these findings propose that SorLA may critically influence amyloidogenic events underlying the AD pathology and nominate the receptor as a potential target for the therapeutic interventions.

The physical interaction of SorLA with APP occurs within the complement-type repeats cluster of SorLA. The two proteins form a 1:1 stoichiometric complex observed more efficiently at acidic rather than neutral
pH. This finding fosters a model of SorLA and APP interacting inside of the secretory and endosomal vesicles where the luminal pH is maintained in a range of 5.5 – 6.5, as opposed to the neutral pH at the cell surface [99]. Maturation of APP O-glycans in the Golgi compartment is required for the APP precursor release into the secretory pathway, determining how APP cleavage is regulated, thus affecting the formation of its soluble forms (sAPPα and sAPPβ) [191, 192]. Interestingly, engineered SorLA mutants were found to influence the APP breakdown by regulating its O-glycosylation, which exemplifies yet another mechanism how this receptor interferes with amyloidogenesis [99]. Furthermore, a splice variant of SORL1 that incorporates a novel exon 30B and denoted SORL1-30B, is present in most brain regions with the highest expression in the temporal lobe and the hippocampus [193]. The receptor variant specifically lacks the binding sites for Aβ and APP, leaving the rest of the receptor intact. This observation suggests that alternative transcription may provide SorLA the ability to control the ligand specificity.

Besides APP trafficking and processing, SorLA controls additional events in the amyloidogenic cascade. Overexpression studies by Spoelgen et al. showed that SorLA’s cytoplasmic tail forms a protein complex with BACE1, a secretase initiating the proteolysis of APP. As SorLA interacts with both BACE1 and APP, the authors proposed that SorLA can render APP less accessible to the secretase, by which it prevents the formation of the BACE1-APP complex in the endosome, thus reducing the APP cleavage. SorLA-BACE1 interaction therefore directly affects APP processing and Aβ production [114]. Importantly, the secreted form of the receptor, sSorLA, is released into CSF, which was found to positively correlate with sAPPβ and Tau in AD patients [194].

SorLA has been also demonstrated to bind ApoE at the cell surface and mediate ApoE-dependent Aβ endocytosis. A biochemical study by Yajima et al. revealed a stronger binding of ApoE4 isoform to SorLA when compared to ApoE3. On the other hand, ApoE2 isoform exhibited the lowest affinity for SorLA. Similarly, SorLA mediated higher cellular uptake of ApoE3 and ApoE4 in contrast to ApoE2 isoform. The same isoform preference was observed when examining the ApoE-dependent uptake of extracellular Aβ by SorLA [110]. Although these findings suggest a role of SorLA in clearing out extracellular ApoE/Aβ oligomers in an ApoE-isoform-dependent manner, a caution should be taken to its physiological relevance since the experiments were conducted in cell lines that overexpress the receptor. Indeed, Carlo et al. failed to show accumulation of ApoE on endogenous levels in mice genetically deficient for Sorl1, thus questioning the significance of this endocytic pathway [93]. SorLA engages in Aβ metabolism also through their direct interaction [111]. Structural studies demonstrated that Aβ can physically interact with a peptide-binding site inside of the propeller tunnel of the VPS10p-domain [109]. Although unable to mediate Aβ uptake when overexpressed in mice, SorLA could target newly generated Aβ peptides from the late endosomal compartment to the lysosomes for its degradation, thereby controlling the amount of Aβ secreted into the extracellular space [109, 111]. Accordingly, a SORL1 variant p.G511R that segregates with AD in a family [87] was impaired in Aβ binding to the VPS10p-D, providing a mechanistic link how disturbed SorLA functionality may increase Aβ levels [111]. Impairments in these processes may increase neuronal vulnerability, a feature that could escalate the intracellular concentration of Aβ, and thus provide extensive pool of peptides to form cytotoxic AβO.

SorLA is linked to AD also through its interaction with subunits of retromer [177, 195], an evolutionary conserved heteropentameric complex and key player in neuronal protein endosomal recycling [196]. The complex is required for cargo export from the endosome both in the retrograde pathway to Golgi/TGN and recycling to the cell surface [195, 197, 198]. Retromer is composed of two sub-complexes: the trimer VPS26-VPS29-VPS35 forming the core assembly, and the dimer of sorting nexin proteins (i.e. SNX-1 and SNX-2) binding to phosphatidylinositol phosphate membrane lipids [195]. The interaction between SorLA and the retromer occurs via binding of the VPS26 subunit to a hexameric FANSHY amino acid sequence located in the cytoplasmic tail of SorLA. The deletion of the retromer binding site in SorLA is correlated with defective endosomal sorting and the consequent misguidance of cargo proteins. These findings are in agreement with SorLA and retromer forming a functional unit that engage in neuronal endosomal recycling [177]. The tail of SorLA also interacts with SNX-27, another trafficking component that mediates recycling of specific receptors (e.g. AMPAR or NMDAR) from the endosomes to the cell surface, which is often retromer-dependent [176]. Similarly to retromer, SNX-27 downregulation has been linked to AD via increased intracellular production of Aβ [199]. These processes are depicted in the (Fig. 3).

**SorLA in AD-related neurotrophin signaling and synaptic transmission**

Rohe and colleagues showed that BDNF is a specific enhancer of Sorl1 transcription in vitro and in vivo, whereas Sortilin expression was not altered [137]. Accordingly, BDNF treatment was able to reduce Aβ production in the brain of wild-type mice but not of SorLA-deficient animals. These data were supported by neuronal
differentiation experiments using human induced pluripotent stem (iPS) cells from AD patients carrying SNPs in SORL1 [200]. The authors screened a number of SORL1 genetic risk variants for their ability to respond to BDNF and to produce Aβ. Individuals carrying mutations in the 5’ end of SORL1 gene showed reduced response to BDNF. Together, the studies demonstrate that SorLA is required for BDNF to decrease the production of Aβ peptides [137, 200]. These findings may have therapeutic potential as the induction of SorLA via BDNF treatment reduces the production of Aβ by 40% (Fig. 4, BOX A) [137]. Later studies uncovered that the BDNF receptor TrkB is not only upstream but also downstream of SorLA. Hence, SorLA can physically associate with TrkB to enhance its anterograde and retrograde trafficking between the cell body and its synaptic destinations, thereby potentiating BDNF-dependent neurotrophic signaling and synaptic plasticity (Fig. 4, BOX C) [143]. Any impairments in this machinery via abnormal SorLA activity therefore likely reduces neurotrophic signaling, synaptic plasticity and ultimately deterioration of synapses, and thus propel the neurodegenerative processes.

More recently, a new role for SorLA in signal transduction recently surfaced thanks to its interaction with Ephrin type-A receptor 4 (EphA4) [96], a tyrosine kinase regulating synaptic structure and functionality [201]. EphA4 binds multiple ligands at the plasma membrane, such as Ephrin A1, which is necessary for EphA4 clustering and its subsequent activation prior to axonal outgrowth and synaptic plasticity [202]. EphA4 exhibits altered distribution in hippocampus of AD patients, where it localizes in Aβ plaques [203]. Aβ oligomers bind EphA4 leading to aberrant activation of the receptor, which ultimately enhances synaptotoxicity and memory deficits in AD mouse models. This interaction is inhibited by SorLA [204–206]. While SorLA does not modulate EphA4 localization, it reduces the aberrant clustering and activation of EphA4/c-Abl pathway triggered by intracellular AβO, particularly in response to Ephrin A1 ligand binding. This is why EphA4 may become a novel therapeutic target for AD [204]. SorLA interacts with the extracellular region of EphA4 via its YWTD/EGF-like domain, by which it controls growth cone collapse in hippocampal neurons [96]. Interestingly, a SORL1 genetic variant translating into SorLA-T947M receptor mutant was identified in LOAD patients, and carries an amino acid substitution in the YWTD domain [207]. Functional studies exploring this mutation further demonstrated that SorLA-T947M is unable to bind EphA4 (without or in presence of Ephrin A1), and to repress its Aβ-dependent activation. Strikingly, elevated EphA4 activation in human AD brains correlates with the reduced SorLA-EphA4 association [96]. Huang et al. also showed that SorLA-mediated inhibition of EphA4 improved spatial learning and memory of mice injected with human AβO. This mechanism might thus be fundamental for the potential use of SorLA as a neuroprotective agent against cognitive impairment in AD patients resulting from abnormal activation of EphA4. SorLA interaction with EphA4 signaling is schematized in (Fig. 4, BOX B).

Overall, the versatility of SorLA as a crucial player in distinct sorting pathways, amyloidogenic, neurotrophic as well as neuroprotective processes makes the receptor a powerful clinical target for approaching synaptic plasticity impairments, and impeding the AD onset and progressive neurodegeneration.

**SorLA in AD-related pathology and associated disorders**

AD etiology is influenced by non-genomic risk factors such hyperglycemia and insulin resistance, dyslipidemia, and obesity, which may explain why AD is commonly comorbid with diabetes mellitus, cardiovascular diseases, and metabolic syndrome [3]. In the past decade, elevated levels of circulating sSorLA have been correlated to increased body mass index and adiposity [149, 208], and to increased intima-media thickness of carotid arteries in patients with organic coronary stenosis and Type 2 diabetes mellitus [3, 209, 210]. Indeed, overexpression of SorLA in vascular smooth muscle cells enhances their migration from media to intima layer, a key step for formation of atherosclerosis. Hyperglycemic condition was proposed as a promoting factor for SorLA expression in the intimal cells that could contribute to stenosis [209].

Expression of lipoprotein receptors is commonly regulated by lipids, for example essential fatty acids and cholesterol. Accordingly, Sorl1 expression can be induced by Omega-3 docosahexaenoic fatty acid in primary cortical neurons [211]. Interestingly, obesity and caloric intake in Type 2 diabetes mellitus patients with morbid obesity and cognitive decline enhance SORL1 expression in peripheral mononuclear cells of plasma, together with other AD-related genes such as APP, PSEN2, ADAM9, and GSK3β. Such expression profile is reduced after gastric bypass surgery [212] or diet [212, 213]. However, interesting data came from a rat model of mild cognitive impairment and dementia. These rats were chronically fed with high-fat diet to become metabolically obese but of normal weight. In contrast to the peripheral blood, the expression analysis of hippocampi revealed decreased Sorl1 and Sort1 mRNA levels while expression of APP, TNFa and CASP3 remained increased [214]. Strikingly, patients of normal weight suffering with metabolic syndrome also exhibit decreased SorLA levels in peripheral blood mononuclear cells [215]. Such findings indicate different regulatory mechanisms of SorLA induction in the brain compared to the peripheral tissue. This should
be taken in consideration when targeting SorLA in AD patients since high levels of sSorLA might contribute to the development of non-genomic AD risk factors.

The role of SorLA in regulating energy metabolism was also supported by functional experiments. Whittle et al. showed that enhanced sSorLA suppresses thermogenesis in adipose tissue by inhibiting BMP/TGFβ signaling [149]. Strikingly, SorLI-/- mice are protected from high-fat diet obesity due to increased browning of white adipose tissue (WAT), and hypermetabolism [149, 208]. Schmidt et al. further proposed the existence of a dosage effect of SorLA on obesity and glucose intolerance as SorLA overexpression in WAT blocked hydrolysis of triacylglycerides and caused excessive adiposity [208]. SorLA expression in WAT was also positively correlated with insulin-induced suppression of lipolysis, and inversely with lipolytic enzyme activities. They suggested that SorLA expressed by adipocytes in WAT functions as a sorting and recycling factor for insulin receptor (IR) that redirects IR molecules from endosomes to the plasma membrane, to enhance IR surface expression, and to reinforce insulin signaling [208]. Interestingly, high expression of SorLA was also found in adipocyte precursors in juvenile visceral WAT. The authors proposed that upon high-fat diet, elevated levels of SorLA in these cells increases their sensitivity to insulin stimulation, which promotes the mitotic expansion of the visceral precursor cell pool in juvenile mice. In contrast, low levels of SorLA in subcutaneous precursors blunt their response to insulin, and prevent their proliferation [216]. Taken together, these studies highlight the complex regulation of SorLA expression and its functional versatility, underscoring SorLA as a key regulator also of activities that might not be directly involved in canonical AD pathophysiology, but could further contribute to it.

**Sortilin biology and its role in AD**

Belenguez et al. recently identified SORT1 as a high-impact AD risk gene [14]. The magnitude of the association was similar whether the patients were diagnosed by questionnaires or clinical evaluation, which substantiates the robustness. Among the SNPs, the lead observations encoded a rare missense variant that substitutes an arginine with a glutamic acid at residue 302, which is located in the β-propeller of the VPS10p-domain, and harbors the ligand binding site. In a Swedish cohort, Anderson et al. identified SORT1 SNPs that are associated with reduced disease risk, suggesting the existence of gain of function variants [217]. On contrary to SorLA, Sortilin protein levels are higher in temporal cortex and cerebellum of some AD patients, and in a transgenic mouse model of AD (APP/PS1ΔE9) [103, 104, 113, 218]. It has been suggested that this increase positively correlates with the severity of AD pathophysiology since no changes are observed in patients with mild cognitive impairments [219]. One explanation for this apparent paradox could be that increased Sortilin may act as a compensatory event to counteract disease progression in those AD patients not harboring a risk SORT1 SNP. Interestingly, C-terminal fragments of Sortilin are deposited in neuritic Aβ plaques in human cerebrum [218] but not in brains from transgenic AD mouse models nor aged macaques exhibiting amyloid plaque deposition [220] suggesting the interspecies differences in the formation/composition of senile plaques in regards to VPS10p-D receptors. Despite an overlap in the sorting machinery used by Sortilin and SorLA, their structural difference and opposite regulation of expression suggest that they exhibit distinct activities in AD pathogenesis.

Sortilin was identified as the second member of the VPS10p-D receptor family in 1997 [221]. Its expression is highly abundant in the CNS and in peripheral nervous system (PNS) neurons [142, 222], and it is enriched in forebrain, particularly in temporal cortex [222, 223]. Sortilin binds a vast number of ligands to control their sorting or signaling activities [153]. Important roles of Sortilin is to mediate anterograde trafficking from the secretory pathway along neurites and to endosomes and lysosomes, and to mediate endocytosis and retrograde transport from the cell surface to the TGN by evading lysosomal targeting and degradation [224]. The low pH within the endolysosomal compartments causes conformational change and dimerization of Sortilin. This results in collapse of the binding site, which triggers the release of Sortilin’s cargo, and enables recycling of the receptor back to the cell surface by TGN-coupled retrograde transport [155]. Similarly to SorLA, Sortilin trafficking pattern is controlled by binding to a number of cytoplasmatic proteins including GGA1-3 [224], AP1 and -2 [225], Rac-p21-activated kinases 1 to 3 (PAK1-3) [226], and Ras-related protein (Rab7b) [227]. The retromer complex also binds Sortilin and is required for its proper sorting [228, 229]. Interestingly, Belenguez et al. also identified the retromer subunit SNX-1 as a novel top-risk gene for AD, similarly to SORT1 [14].

Among other ligands, Sortilin transports BACE1 and APP, by which it regulates the production and endocytosis of sAPP [97]. Similarly, Sortilin facilitates the uptake of AβO [112] and ApoE [93]. Perhaps most well established is the role of the receptor in regulating neurotrophic signaling. It forms a receptor complex with p75NTR at the plasma membrane by which it modulates binding of proNTs, and controls their pro-apoptotic activity [52, 53, 134, 140]. Sortilin also enables the anterograde transport of neurotrophin receptors such as TrkB and the secretion of its ligand BDNF [138, 142], the latter being dependent
on the complex formation with Huntingtin associated protein-1 (HAP1) [230]. Sortilin undergoes ectodomain shedding at the cell surface as well as during intracellular trafficking which inhibits lysosomal degradation of its cargos including BDNF [117]. Put together, any impairment of Sortilin function affects cell survival and homeostasis in the brain, particularly during aging [53]. In the following paragraphs, we will discuss studies that highlight the function of Sortilin in AD and related disorders.

**Sortilin interactions in amyloidogenic cascade**

Sortilin transports BACE1 and APP [97, 103, 105], and regulates the production and endocytosis of sAPP [97]. The intracellular trafficking of BACE1 between TGN and endosomes is necessary for its functioning [231, 232], and it is governed by adaptor proteins including GGA3 [233], which targets BACE1 for its lysosomal degradation [234]. Accordingly, inhibition of GGA3 activity results in local, cytotoxic accumulation of BACE1 in axonal swellings leading to enhanced BACE1 activity, and later axonal dystrophy observed even before enhanced levels of Aβ [235]. Indeed, reduced levels of GGA3 protein in AD brains correlate with increased levels of BACE1, APP, and Aβ [234, 236]. Sortilin cytoplasmic tail also contains a consensus motif for binding GGA adaptor proteins that facilitates Sortilin transport from the Golgi compartment to endosomes and lysosomes [224, 237, 238]. Finan et al. showed that Sortilin forms a complex with BACE1 in the human brain, by which it regulates retrograde trafficking of BACE1 from the early endosomes back to the perinuclear region of TGN (Fig. 5, BOX B). The authors further suggested that Sortilin-BACE1 interaction facilitates BACE1-mediated first cleavage of APP, leading to an increased formation of sAPPβ and accumulation of Aβ peptides. Importantly, they showed that this process is partially regulated by Sortilin’s but not by SorLA’s or SorCS1b’s cytoplasmic tails [103]. These data highlight the non-redundant, pro-amyloidogenic function of Sortilin, and the specificity of its cytoplasmic tail in BACE1-dependent first cleavage of APP (Fig. 5, BOX C).

Later studies revealed that Sortilin’s extracellular domain can bind APP in vitro and in vivo [97, 105], and that Sortilin is a substrate for all three secretases involved in APP processing [91, 115, 117, 118, 239, 240]. The α-secretases ADAM10 [117, 118] and ADAM17 [115] that are responsible for the first non-amyloidogenic cleavage of APP, also facilitate Sortilin ectodomain shedding [117]. Interestingly, Sortilin is a target of γ-secretase [91, 239], and it has been a predicted substrate for BACE1-mediated processing [240]. These data suggest that Sortilin might be cleaved in the same subcellular compartments as APP, perhaps when bound to each other. Indeed, Yang et al. showed that Sortilin co-localizes with APP in perinuclear space and in axons of cultured neurons, where it facilitates APP trafficking from the late endosomes to the lysosomes for its degradation [105]. Remarkably, C-terminal fragments of Sortilin liberated by γ-secretase are deposited in neuritic Aβ plaques of human cerebrum [218]. Even though there is no experimental explanation yet, one might speculate that Sortilin can be sequentially processed when in complex with APP resulting in shedding of Sortilin’s ectodomain by the α-of β-secretase, later followed by γ-secretase cleavage. The C-terminal tail may be then either released from neurons, and subsequently captured in Aβ plaques, or it may associate with Aβ already intracellularly, and be released upon neuronal demise. Both possible interpretations are schematized in (Fig. 5, BOX A).

The cleavage of APP and ectodomain shedding of Sortilin may explain why the C-terminal domain of the receptor accumulates, and represent a prominent constituent of the amyloid plaques [218, 220]. However, these data were contradictory with Gustafsen et al. who proposed that APP and Sortilin primarily co-localize in the neurites [97]. Gustafsen et al. found that Sortilin directly enhances the production of secreted sAPPα, and mediates uptake of the extracellular sAPP. Interestingly, the authors detected decreased levels of sAPPβ in the presence of Sortilin, contrary to the Finan study [103]. The authors proposed that Sortilin increases APP processing in non-amyloidogenic pathway (sAPPα) when compared to the pro-amyloidogenic pathway (sAPPβ). This is in contrast to SorLA that reduces the levels of both, sAPPα and sAPPβ [97]. These observations are supported by a recent study by Ruan et al. that used a triple transgenic AD model (APP/PSEN1) deficient in Sortilin. They reported that the lack of Sortilin enhances the Aβ deposition, neuronal loss, and astrocytic activation during aging. They also demonstrated that Sortilin’s intracellular domain mediates APP degradation [104]. According to these studies, Sortilin thus has a neuroprotective feature against APP-dependent amyloidosis likely because it consequently decreases the cleavage of cytotoxic sAPPβ. These two opposing models are depicted in (Fig. 5, BOX C). Nevertheless when combined, these studies demonstrate that the proteolytic cleavage of APP differs dependent on the expression levels, protein localization, and perhaps activity of the specific VPS10p-D receptors. For example, high Sortilin levels might increase APP cleavage and Aβ release, while increased SorLA retains APP in TGN, thus protecting the cell against cytotoxicity. However, the biochemical studies addressing Sortilin localization and the mechanism of its action on APP processing are not consistent, likely due to the differences between the experimental models. For instance, the Finan and
Yang studies employed a C-terminally tagged Sortilin variant [103, 105], whereas Gustafsen et al. used the untagged receptor [97]. The C-terminal tagging will likely lead to aberrant Sortilin localization since binding of the GGA adaptors requires the C-terminal acid cluster of the receptor tail, as demonstrated by Cramer et al. [241]. More functional studies using either untagged proteins or both models in parallel are required to determine the precise molecular mechanism by which Sortilin regulates APP transport and catabolism in non/amyloidogenic pathways.

It is well established that Sortilin forms a receptor complex with p75NTR which mediates pro-apoptotic cell responses [52, 134]. Accumulation of extracellular Aβ oligomers facilitates the neurotoxicity and neuronal cell death via their physical binding to p75NTR [242], while the addition of Aβ peptides increases expression of Sortilin in vitro likely via activation of the p75NTR/RhoA pathway [113]. In line with these data, Takamura et al. found that...
extracellular AβO, as opposed to non-oligomerized Aβ, act as Sortilin ligands, and that Sortilin loss-of-function suppresses AβO-targeted autophagy and AβO-induced cell death [112]. Interestingly, extracellular AβO triggers the co-localization of Sortilin with p75NTR at the neuronal surface, proposing a model where Sortilin-p75NTR receptor complex mediates apoptotic response upon binding of AβO, a mechanism that can contribute to the progressive neurodegeneration in AD patients [112].

Besides regulating the amyloidogenic cleavage of APP, Sortilin is the major neuronal ApoE receptor for endocytic uptake and catabolism of Aβ [93]. Binding studies revealed that Sortilin is able to interact with each of the three major ApoE variants with slightly higher affinity for the cytotoxic ApoE4 [93]. Carlo et al. further showed that crossing AD mice (PDAPP and FAD lines) with mice deficient in Sortilin increases Aβ and ApoE levels in cortex and hippocampus [93]. There was no difference in sAPPα, sAPPβ, and BACE1 expression. Importantly, no changes in ApoE levels were seen in glia cells, known to be the main site of apolipoprotein synthesis. Remarkably, however, the absence of Sortilin significantly attenuated cellular uptake of ApoE-Aβ complexes, demonstrating that impaired ApoE clearance by Sortilin causes accumulation of Aβ in the brain [93]. Given Aβ handling was unchanged in knockout neurons in the absence of ApoE, this suggests that Sortilin exclusively but potently mediates the Aβ uptake when in complex with ApoE. These observations were in marked contrast to SorLA deficient mice that exhibited no accumulation of ApoE, supporting the model of Sortilin’s direct effect on ApoE and Aβ turnover [93]. Most recently, the same research group studied the relevance of the Sortilin-mediated uptake of ApoE for brain lipid metabolism [243, 244]. They found that Sortilin is required to accumulate and facilitate the metabolism of polyunsaturated fatty acid into endocannabinoids; lipids with potent anti-inflammatory and neuroprotective functions. Remarkably, Sortilin expression had no impact on endocannabinoid production in the model of Sortilin’s direct effect on ApoE and Aβ turnover [93]. The authors explain this apparent paradox by ApoE4 being unable to uncouple from Sortilin in the endosomal compartment, which disrupts recycling and re-exposure of the receptor at the plasma membrane. The combined findings are schematized in (Fig. 5, BOX D) and suggest a protective role of Sortilin in AD by lowering Aβ levels, reducing production of neuroinflammatory cytokines [244, 245], stimulating synapse function, and sustaining neuron viability.

Sortilin in AD-related neurotrophin signaling and synaptic transmission

Sortilin is also an important neurotrophic receptor. The proneurotrophins proBDNF, proNGF, and proNT3 can form ternary complexes with Sortilin and p75NTR, which promotes signaling towards neuronal cell death [52, 53, 134, 140]. For instance, the proNGF-Sortilin-p75NTR complex is fundamental for pruning of retinal ganglion cells, and is involved in degeneration of acutely injured and senescent neurons [53]. Surprisingly, Sortilin and p75NTR also support trophic activities induced by mature neurotrophins. While it was well-established that p75NTR strengthens binding of NGF, BDNF and NT3 to their cognate receptor [9], Vaegter et al. found that Sortilin works in tandem with p75NTR to empower neurotrophin signaling by facilitating the anterograde transport of their respective Trk receptors along axons to postsynaptic densities [142]. In particular, they found that peripheral neurons in Sortilin deficient mice on the genetic background of p75NTR−/− were normally developed but underwent a marked age-dependent neurodegeneration leading to severe neuronal demise, and sensory and motor impairments [142].

Sortilin also regulates BDNF secretion. proBDNF sorting to lysosomes is blunted upon ADAM10-mediated and activity-dependent Sortilin’s ectodomain shedding from the cell membrane and intracellular compartments, thus providing more BDNF for secretion [117]. Interestingly, proBDNF binding to HAP1 is important for Sortilin to traffic proBDNF in neurites, and to stimulate BDNF processing and secretion [138, 230]. Sortilin may also target proBDNF for lysosomal degradation to blunt BDNF secretion [117]. When and how Sortilin acts as a regulatory switch to increase or decrease BDNF secretion has not yet been resolved, but possibly the levels of the receptor expression are involved. To further increase the complexity, proBDNF increases the expression of Sortilin and p75NTR in vitro. This prevents proteolytic cleavage and processing of proBDNF, possibly as a consequence of its binding to the high-affinity Sortilin and p75NTR receptor complex [113, 134]. Chen et al. showed that binding of proBDNF to Sortilin is mediated by the prodomain of proBDNF (amino acids 44–102), and that this interaction is reduced in the BDNF-Val66Met mutated protein [138]. They further showed that Sortilin traffics wild-type BDNF into the pathways for regulated secretion, whereas the BDNF-Val66Met mutation disrupted this sorting [138]. The reduced binding of BDNF-Val66Met to Sortilin may explain the faster cognitive decline in AD that harbors this mutation [37–39]. A recent study from Fleitas et al. further proposed that accumulation of reactive oxidative species (ROS) in AD patients stabilizes proBDNF
and decreases proapoptotic signaling and blunts trophic actions of BDNF [57]. The authors examined hippocampal tissue from AD patients and found a significant increase in Sortilin and proBDNF levels, which translated into an enhanced proBDNF/BDNF ratio in CSF of the patients. Strikingly, when the authors applied CSF from AD patients on cultured WT hippocampal neurons, they observed enhanced proBDNF-p75NTR-dependent apoptosis in contrast to CSF from healthy controls [57]. These data propose the proBDNF/BDNF ratio as a biomarker for AD diagnosis or disease progression.

A hallmark of AD is the early and progressive dysfunction, synaptic loss, and degeneration of basal forebrain cholinergic neurons (BFCN). The reason for their selective vulnerability is not fully understood but BFCN are reliant on mature NGF that is produced by and transported retrogradely back from their target neurons in cortex and hippocampus. In AD patients, NGF levels and TrkA expression are decreased in BFCN whereas proNGF is increased [10, 62, 74, 246]. Given the expression of p75NTR and Sortilin is preserved in AD brains, these alterations favor an increase in proapoptotic signaling on the expensive trophic stimulation. Indeed, transgenic mice expressing an anti-NGF-antibody localized in lipid rafts [251] that regulates neuronal excitability and neurite outgrowth [252]. PrP inhibits BACE1 and Tau expression, which subsequently reduces the levels of Aβ in the brain [253]. During AD, PrP converts into its polymerizing, misfolded form called scrapie isoform PrPSc, which binds AβO, and transduces their cytotoxic signals across the neuronal membrane [254–256] causing synaptic failure and cognitive impairments [257–261]. Upon AβO binding, PrP is phosphorylated by Fyn kinase leading to hyperactivation of NMDAR channels, and subsequent glutamate toxicity. Furthermore, AβO-PrP complex physically binds its co-receptor the metabotropic glutamate receptor 5 (mGluR5), which activates the Fyn kinase, followed by eEF2 phosphorylation, and consequent loss of neuritic spines and memory [262–264]. At the plasma membrane, PrP binds Aβ oligomers with high-affinity, yet during aging, AβO-PrP complexes eventually accumulate extracellularly in form of plaques, even before AD manifestation [265]. Thus, targeting receptors involved in AβO signal transduction such as PrP and mGluR5, or disrupting the AβO-PrP complex holds therapeutic potential in AD patients [266]. Indeed, a recent study discovered that a PrP antagonist blocks the protein aggregation, and rescues the Aβ-related synapse loss and memory deficits in AD transgenic mice [267], similarly to mGluR5 antagonist [262]. Strikingly, Uchiyama et al. showed that Sortilin is neuroprotective against the prion spreading as it internalizes PrP and PrPSc, and transports them into lysosomes for their degradation. However, PrP can be a determinant of Sortilin activity since increased accumulation of cytotoxic PrPSc leads to lysosomal degradation of Sortilin resulting in progressive propagation of PrPSc [268]. Accordingly, Sortilin deficiency leads to early accumulation of PrPSc, and accelerated disease progression and death of the mice. These observations pinpoint the neuroprotective role of Sortilin sorting against protein misfolding and prion-related spreading that might include internalization of other proteins than just Tau and PrP.

Along with aggregation of TAR DNA-binding protein 43 (TDP-43), Tau pathology is also a hallmark of frontotemporal dementia (FTD) [269]. Haploinsufficiency for GRN, a gene encoding progranulin (PGRN) that is a protein with widespread neuroprotective and anti-inflammatory functions, is one possible causative for FTD [270]. Haploinsufficient patients have a 50% reduction in PGRN levels, why inhibiting its clearance from the brain extracellular space has been proposed as a therapeutic approach. In a human cohort, a SNP in SORT1 that increases Sortilin expression is associated with reduced plasma PGRN concentration [271]. Hu et al. found that Sortilin binds PGRN and mediates its endocytic uptake and extracellular clearance, and that preventing

Sortilin in AD-related pathology and associated disorders

Increased Tau phosphorylation, its subsequent misfolding and prion-like spreading are common pathological features in AD brains [4]. By using mutant Tau transgenic mice (P301S), Johnson et al. found that Sortilin activity suppresses replication of Tau prion in the forebrain thus protecting it against neurotoxic pTau aggregation. On contrary, Sortilin expression is lower in the hindbrain where it does not protect against p-Tau accumulation [223]. AD shares several other mechanisms with Prion diseases, a group of fatal neurodegenerative disorders which major genetic component is neuronal Prion protein (PrP). PrPC is a transmembrane receptor localized in lipid rafts [251] that regulates neuronal
its function can normalize PGRN levels in Grrt+/− mice [273]. Accordingly, a phase II clinical trial using a Sortilin inhibiting antibody recently achieved positive results in FTD patients [270].

TDP-43 pathology is also common in AD with more than 55% of the patients having these inclusions [273]. Interestingly, SORT1 can be alternatively spliced to generate an mRNA transcript named Ex17b that includes a premature stop codon translating into a truncated soluble receptor variant that retains its ligand binding abilities [274, 275]. In the healthy brain, nuclear TDP-43 inhibits this splicing which leads to exclusion of Ex17b, and expression of the full-length receptor. In FTD and AD, the nucleus is depleted from TDP-43, favoring its cytoplasmic aggregation. This will drive splicing and produce the soluble and dominant-negative Ex17b decoy receptor [274, 275]. The functional link between Sortilin, FTD, and AD is further supported by Bellenguez et al. who, in addition to SORT1, also identified GRN as a critical risk gene in AD [14]. Remarkably, the rare Sortilin K302E variant, which is a predicted loss of function mutation in AD [14], has been also identified as a causal patient-only variant in FTD patients [94].

Sortilin has been also extensively studied for its contribution to hyperlipidemia, cardiovascular disease, diabetes mellitus, obesity, and metabolic syndrome [275, 276]. In the following paragraphs we will pin point the key observations on Sortilin's involvement in glucose and lipid metabolism, while we refer to these two recent reviews [276, 277] for complete overview of the topic.

Obesity in humans and mice is associated with down-regulation of Sortilin in subcutaneous WAT and liver [278–280], while Sortilin deficiency results in slower weight gain on western diet [281, 282]. These findings are in contrast to SorLa which expression is upregulated upon hyperglycemic condition, obesity, and high caloric intake [209, 212, 213]. Interestingly, Sort1−− mice on the genetic background of the LDL receptor (LDL-R) knockout exhibit improved function of brown adipose tissue [283]. These data point at a negative feedback-loop where high body mass index down-regulates Sortilin expression to prevent further weight gain. Other studies reported that deprivation of glucose attenuates Sortilin levels in skeletal muscle [284], and that insulin resistance induces hepatic degradation of Sortilin in mice [285], suggesting Sortilin's role also in glucose homeostasis. Indeed, Sortilin enables the biogenesis of glucose transporter 4 (GLUT4) storage vesicles by binding and targeting GLUT4 into matur- ing vesicles, and by controlling GLUT4 recycling [286–290]. When insulin levels decline, GLUT4-positive vesicles are retrieved from the plasma membrane to the endosomal compartment. Here, the cytoplasmic tail of Sortilin will engage the retromer complex, enabling GLUT4 retrograde transport and reuse [291]. Paradoxically, studies on Sort1−− mice have so far not shown any signs of insulin resistance or reduced glucose handling [282, 292]. Only one study found increased glucose uptake and insulin sensitivity [282].

A vast number of GWAS have identified SNPs in SORT1 strongly associated with LDL cholesterol and risk of cardiovascular disease [277]. Kathiresan et al. [293]and Musunuru et al. [294] were first to identify a SNP that associated with LDL cholesterol. Carriers of the minor allele have lower LDL and increased hepatic expression of Sortilin, suggesting that Sortilin is protective against cardiovascular disease. Unfortunately, studies in mice have yielded conflicting results about the directionality of LDL cholesterol versus levels of Sortilin expression. Using viral-mediated overexpression, Musunuru et al., confirmed an inverted correlation between Sortilin expression plasma LDL [294]. A similar directional correlation was confirmed by Rader's group who suggested that Sortilin destines LDL for lysosomal degradation during its biosynthesis, and enables hepatic LDL clearance [280, 295, 296]. In marked contrast, Kjølby et al. showed the opposite correlation; i.e. low Sortilin expression equals low LDL cholesterol [297]. The authors demonstrated that Sortilin facilitates the formation and hepatic export of ApoB10-containing lipoproteins. Another study reported that Sortilin also supports secretion of Prorprotein convertase subtilisin/kexin type 9 (PCSK9), which targets the LDL receptor for degrada- tion, thereby further increasing plasma cholesterol [298]. The confusion for the discrepant results remains, with a similar number of papers arguing for a positive and negative correlation between Sortilin expression and plasma lipids, respectively. The conflicting results from animal models have been largely discussed [276, 277], and might be explained by the strong interplay between glucose and lipid metabolism, which is highly regulated by the composition of diet, weight, age, genetic background, and hormonal stimulation. Moreover, Sortilin expression itself is greatly regulated by metabolic activity and, as described in the previous sections, even minor changes in receptor expression may have substantial functional implications, similarly to SorLa.

To conclude, there is substantial evidence that Sortilin regulates a number of activities involved in Ap production and clearance, neurotrophic signaling, tau pathology, prion-related spreading, as well as metabolic disorders that are comorbid with AD. The complex modalities by which Sortilin operates with some functions being protective and others detrimental, may explain why certain SORT1 SNPs reduce whereas others increase the AD risk.
SorCS1 biology and its role in AD
SorCS1 was identified as the first SorCS protein from mouse brain by Hermey et al. in 1999 [129], followed by SorCS2 and SorCS3 in 2001 [123, 131]. SorCS1, 2 and 3 hold high structural homology, and thus they likely partially overlap in their functions when expressed in the same tissue. They mostly differ from each other in their cytoplasmic tail, which interacts with various adaptors to control cellular trafficking and signaling [121, 131]. SorCS1a is unique as it exists in (at least) five isoforms, SorCS1a-e, that vary in their cytoplasmic tails and in their expression pattern. When overexpressed, murine SorCS1a undergoes rapid internalization via its binding to clathrin adaptor AP-2, whereas SorCS1b predominates at the plasma membrane, and shows little trafficking activity [299]. Rather, SorCS1b may engage in signal transduction given that its cytoplasmic tail contains consensus sequences for a SRC Homology 3 Domain (SH3) binding motif. SH3 motif is recognized by protein tyrosine kinases including Src family such as Src, Fyn, Blk or Lyn, which regulate many cellular functions including cell proliferation, differentiation, migration, and survival [300]. SorCS1c can bind VPS35, the core protein of the retromer complex that controls transport out of the endosomal compartment but its intracellular domain also harbors interaction site for adaptors involved in cellular signaling [106, 133, 148, 299]. As a consequence, SorCS1 is present both in the soma, dendritic vesicles, and at the plasma membrane in neurons [107, 301, 302] (Fig. 6). The physiological functions of the receptor variants are only slowly emerging and needs to be investigated in more detail. SorCS1 can form homodimers as well as heterodimers with SorCS2 and -3 but the functional consequence has not been studied [303]. However, the N-terminal propeptide of human SorCS1 can bind Sortilin, which substantially reduces the ability of Sortilin to mediate cellular uptake of its ligands and hampers its ability to support signaling by ciliary neurotrophic factor [304] (Fig. 6, BOX A). SorCS1 can also bind SorLA and VPS35, while Sorcs1−/− mice exhibit decreased expression of these two genes in the brain [92]. SorCS1 shows the highest expression in neurons from cerebral cortex, amygdala, hippocampus, and thalamus, while it is mostly expressed in forebrain during mouse development [122, 301]. SorCS1 expression is very dynamic and can be regulated by synaptic activity [121, 301]. For example, kainic acid, a glutamate analog, induces high expression of SorCS1 in the hippocampus [121, 301]. More physiologically, SorCS1 has been detected as the most correlated gene expressed in mouse hippocampus after novel object recognition performance [305]. Rao-Ruiz et al. further showed that SorCS1 is upregulated 220-fold in engram cells, the cells that encode a specific memory during memory consolidation [126]. Whether this upregulation is specific to one or more of the splice variants is not known.

SorCS1 involvement in learning and memory is further supported by several human genetic studies that linked SNPs in SORCS1 gene to memory retention [306] and the risk of AD [83, 84, 108, 307–312]. Accordingly, gene expression analysis of amygdala from 19 AD patients revealed significantly lower SORCS1 expression compared to healthy controls [108]. Furthermore, SORCS1 genetically interacts with SNPs in APOE [313, 314], SORCS2 and SORCS3 [84], respectively, to increase AD risk suggesting that these proteins functionally associate in shared actions. Several SNPs in SORCS1 have also been linked to neurodegenerative transmissible spongiform encephalopathies caused by accumulation of PrPSc. Given that prion seeding characterizes many deteriorating brain disorders, it may suggest a broader involvement of SorCS1 in neurodegenerative processes, similarly to Sortilin [315].

SorCS1 interactions in amyloidogenic cascade
There are several functional studies uncovering the importance of SorCS1 in Aβ metabolism. They demonstrated that APP can physically interact with both the SorCS1a, -b, and -c isoforms suggesting that SorCS1 may function in trafficking of and potentially also signaling by APP [106–108, 133]. In accordance with a function in cellular sorting, SorCS1c but not SorCS1b retains APP from insertion into anterogradely transported vesicles in hippocampal neurons [101, 107] (Fig. 6, BOX B). Knockdown of SorCS1a and -c expression in neuroblastoma cells increase Aβ production [107, 108]. Furthermore, the disruption of SorCS1c internalization motif YAQM in its cytoplasmic tail perturbed APP sorting through endosomal compartments, decreased retrograde TGN trafficking, and increased Aβ production, thus resembling SorCS1 loss of function [106]. On the other hand, overexpression of SorCS1a, -b, and -c decreased levels of Aβ, as well as lowered levels of secreted APP products [92, 106, 108] (Fig. 6, BOX D). Studies in SorCS1 knockout mice have confirmed many of the in vitro observations. Hence, receptor deficiency translated into an increase in APP C-terminal fragments in brain of females but apparently the male mice were not affected by SorCS1 deletion [106]. This is especially interesting given that the genetic association between SorCS1 and AD was strongest for women. Strikingly, Hermey et al. recently found that the progressive amyloid plaque formation in aged AD mice (APP/PS1) decreases the levels of SorLA, SorCS1, and SorCS3 in frontal cerebral cortex, and to a minor extent also in hippocampus, forming a virtuous self-amplifying loop [101]. It has also been reported that SorCS1 itself is a substrate for PSEN-dependent γ-secretase cleavage [91].
and ADAM17 α-secretase, which will downregulate the receptor expression, adding yet another loop to the complex function of SorCS1 (Fig. 6, BOX E) [115].

**SorCS1 in AD-related pathology and associated disorders**

Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia and insulin resistance. T2DM is commonly comorbid with AD, increasing the risk of AD diagnosis by approximately 2–3 folds [316–318]. On contrary, approximately 80% of AD patients exhibit insulin resistance and impaired glucose handling [319–321], suggesting that, likely, there are common molecular pathways involved in both disorders. Hyperinsulinemia is associated with impaired cognitive performance, while hyperglycemia increases Aβ accumulation, exacerbate oxidative stress, neuroinflammation, and mitochondrial
dysfunction, ultimately leading to impaired neuronal integrity and neurodegeneration. In recent years, this shared comorbidity is sometimes called Type 3 diabetes mellitus [321–325]. Interestingly, SorCS1 regulates insulin metabolism and secretion as it facilitates the release of insulin from pancreatic β cells [326], in contrast to SorLA which establishes cellular sensitivity to insulin by trafficking the insulin receptor to the plasma membrane [208]. Therefore, it is not surprising that impairments in SorCS1 activity are strongly associated with Type 1 and Type 2 diabetes [327–331]. Strikingly, T2DM has been identified as a contributing risk factor to AD etiology patients carrying SNPs in SorCS1 [332]. Put together, these data suggest that aberrant SorCS1 function in the brain might fail to not only integrate the APP sorting and processing, but also the signaling of another contributing trophic factor, insulin. Impairments in SorCS1 can thus lead to the pathophysiological events that are behind the AD onset and progressive neurodegeneration.

**SorCS1 in AD-related neurotrophin signaling and synaptic transmission**

A function of SorCS1 in neurotrophin signaling has been only sparsely studied. When exploring SorCS1 interactome using recombinant SorCS1-ecto-His protein as a bait in synaptosomes from mouse brain, Savas et al. identified TrkB as a candidate binding partner of SorCS1 [133]. In marked contrast to mice lacking SorLA [143] or Sortilin [104, 142], Subkhangulova et al. further showed increased TrkB signaling in a knock-out mouse line that is devoid in both Sorcs1 and Sorcs3 expression [144]. The authors proposed that SorCS1 binds TrkB and likely facilitates its intracellular trafficking and signaling abilities (Fig. 6, BOX C). Unfortunately, BDNF signaling was not studied in neurons deficient in SorCS1, precluding any conclusions as to whether the effect was reliant on this receptor. Better investigated is the function of SorCS1 in binding of the presynaptic cell adhesion molecules Neurexins, and the regulation of synapse structure. Decreased levels of synaptic membrane proteins like Neurexins [333–335] and enlargement of early endosomes [336] have been proposed as novel biomarkers for AD diagnosis. The trans-binding of Neurexins expressed on the presynapse to Neuroligins that are present at the postsynapse, is required for synaptogenesis and synaptic stabilization. However, Neurexins can also bind AβO, which disrupts the interaction with Neuroligins, leading to severe damages of excitatory synapses [337, 338]. Recently, Joris de Wit’s group described that SorCS1 is a key sorting molecule regulating the axonal-dendritic polarization of synaptic proteins, a critical feature for neuronal wiring and synaptic plasticity [133, 302]. They discovered that SorCS1 localizes into early and recycling endosomes, where it controls trafficking of Neurexin and AMPAR to the neuronal surface. Since SorCS1 expression must be tightly regulated, the overexpression and the loss of SorCS1 activity leads to perturbed sorting and shifted ratio in the localization of Neurexin-1a, AMPARs, Neuroligin, and other polarized synaptic adhesion molecules at the axonal and dendritic surfaces [133, 302] (Fig. 6, BOX F). The imbalance in synaptic proteins distribution is caused by impaired SorCS1 interaction with Rab11-family-interacting protein 5 (Rip11), which governs the transition from early endosomes to Rab11-positive recycling endosomes. The alterations translate into reduced glutamatergic and GABAergic neurotransmission in cortical layer 5, an area where neurons are substantially affected in AD [133]. This is in accordance with observation that fluctuations in Neurexin and AMPA receptor activity sway the balance between excitatory and inhibitory neurotransmission in AD [339]. Notably, GABAergic and AMPA receptor neurotransmission is compromised in AD patients, and such alterations are associated with the cognitive decline [340–342]. Therefore, the impairments in SorCS1-dependent APP catabolism, trafficking of adhesion molecules, neurotransmitter receptors and trophic receptors may jointly cause synaptic dysfunction, synapse loss and neurodegeneration in AD patients. Unfortunately, the molecular mechanisms of SorCS1 signaling are still largely unknown. Future studies should thus functionally address the spectra of SorCS1 isoforms in relations to its binding partners in order to fully understand the regulatory mechanisms directly or indirectly involved in AD pathogenesis.

**SorCS2 biology and its role in AD**

SorCS2 was described by Rezgaoui et al. in 2001 as a gene dynamically expressed during mouse brain development, particularly in dorsal thalamus and midbrain floorplate [123]. In adulthood, SorCS2 is highly expressed in hippocampus (particularly in dentate gyrus, CA2 and CA3 regions), piriform cortex, and in striatal medium spiny neurons [121, 123, 343, 344]. It is localized mostly in somatic vesicles, but also in neurites, dendritic spines, filopodia-rich projections, and in the growth cone of projecting axons [36, 54, 55, 132]. Like other VPS10p-D receptors, SorCS2 engages in cellular trafficking and signaling controlled by its expression and the presence of co-receptors and ligands. Expression of SorCS2 can be altered by external stimuli, which was demonstrated by deep brain stimulation of subthalamic nucleus [127] (Fig. 7, BOX B). This feature is crucial for acute morphological responses, such as neurite regrowth, synaptogenesis as well as disassembling of synapses, and the control of synaptic plasticity [55]. Nykjaer's group showed that
SorCS2 exists in three active isoforms: an immature pro-form, and mature single- and two-chain variants. These isoforms are generated by sequential proteolytic cleavage, and are presented uniquely by neurons and glial cells during intercellular communication in order to activate either trophic (single-chain) or pro-apoptotic (two-chain) signaling [132] (Fig. 7, BOX A). The receptor can also form homodimers which may adopt at least two distinct

Fig. 7 SorCS2 signaling in neuronal networks relevant for AD. SorCS2 is found in neural soma, dendrites and axons. Box A) SorCS2 exists in three isoforms that have different signaling profiles. SorCS2 is initially produced as a proform, which can be cleaved by Furin from its propeptide, giving rise to a single-chain receptor. The single-chain can be further cleaved within the leucine-rich domain, producing a two-chain isoform. Box B) SorCS2 expression changes upon external stimuli, which affects synaptic plasticity. Box C) SorCS2 interactions with neurotrophins. 1. SorCS2 single-chain binds p75NTR and Trio, which mediates Rac1 and Fascin signaling. Fascin activation leads to F-actin filaments assembly and growth cone outgrowth. 2. ProBDNF or proNGF binding to SorCS2 leads to dissociation of Trio causing Rac1 signaling inactivation, actin filaments disassembly and retraction, and grow cone collapse, which is important for synaptic pruning and neuronal wiring. 3. Propeptide of BDNF-WT binding to SorCS2 does not affect the growth cone outgrowth. 4. Propeptide of BDNF with Val66Met mutation exhibits high binding affinity to SorCS2, subsequently dissociating Trio, and inhibiting Rac1 signaling. This pathway promotes elimination of spines and loss of synaptic adaptability. 5. SorCS2 two-chain binds p75NTR, which mediates proBDNF-dependent apoptosis. Box D) SorCS2 controls synaptic plasticity. Upon proBDNF release (1a), SorCS2 mediates synaptic weakening (4a) via its interaction with proBDNF and p75NTR (2a), which induces long-term potentiation (LTP; 3a). SorCS2 and the BDNF receptor TrkB are located outside of the postsynaptic density (PSD). Upon BDNF release (1b), SorCS2 and TrkB relocate to the synapse (2b) where they interact. TrkB binds BDNF, and undergoes phosphorylation and activation (3b), subsequently inducing LTP (4b) and synaptic strengthening (5b). Box E) SorCS2 interacts with synaptic receptors GluN2A/2B, EAAT3, and TrkB at PSD of glutamergic neurons, and regulates their anterograde and retrograde trafficking. Impairments in these processes lead to increased cellular stress and neurodegeneration.
conformations that is controlled by binding of its ligands [135, 303]. Potentially, this might modify its interaction with co-receptors or cytosolic adaptor proteins, and thus regulate SorCS2-dependent signaling and sorting. Among its many functions, SorCS2 facilitates intracellular sorting and distribution of synaptic proteins, and protects neurons from oxidative stress and neuronal death [344, 345]. It also transduces signals that mediate neuronal remodeling and synaptic plasticity [54, 55, 132]. As such, it has been genetically linked to a number of psychiatric and neurodegenerative disorders [344]. Human genetic studies uncovered more than 18 SNPs in SORCS2 that were associated to AD [83, 84]. They also observed epistatic interactions with SorCS1 and SorCS3 in AD patients [84]. Despite the genetic data and established functions in signaling and neurotransmission, SorCS2 is the least studied VPS10p-D receptor when it comes to functions in signaling and neurotransmission, SorCS2 is causative to the neurodegenerative disorder Huntington’s disease [348]. Indeed, SorCS2 has been functionally associated with Huntington’s disease via its interaction with mutated huntingtin protein and its impaired sorting [344]. Combined, there is a substantial evidence that SorCS2 might be involved in several aspects of neurodegenerative processes including its neuroprotective role against cellular stress.

Particularly well studied is SorCS2 function in signaling established by pro- and mature neurotrophins, which is illustrated in Fig. 7, BOX C. ProNGF and proBDNF bind to SorCS2 at the plasma membrane, and both single- and two-chain SorCS2 variants can be in complex with a proneurotrophin ligand and p75NTR [132], forming higher-order signaling assembly [135]. During neuronal development, the SorCS2-p75NTR complex is essential for proBDNF and proNGF to induce growth cone collapse of extending neurites thereby controlling neuronal wiring and connectivity. Notably, this activity is specifically reliant on the single-chain isoform of SorCS2. In contrast, two-chain SorCS2 is required for pro-NTs-dependent induction of glial cells apoptosis [132]. Binding of the cytosolic guanine-nucleotide exchange factor Trio to SorCS2-p75NTR is required for the retraction of extending axon [55]. As demonstrated for proNGF, the engagement of the SorCS2-p75NTR complex with a proNT displaces Trio and downregulates Rac1 signaling while activating Protein kinase C. Jointly, these events destabilize actin filaments, and lead to impaired filopodia retraction and subsequent growth cone collapse [55]. If defective, such impairments perturb neuronal connectivity and synapse function, causing increased neuronal vulnerability and neuronal death in the aging brain [132, 349–351].

The biological function of single-chain SorCS2 is not limited to the neurodevelopmental stage. In the postnatal hippocampus, binding of proBDNF released from the presynapse towards the SorCS2-p75NTR complex located in the postsynapse will induce long-term depression (LTD) and synaptic weakening [54]. Notably, SorCS2 can engage with TrkB to enable the local recruitment of TrkB from extrasynaptic sites to PSD95-positive domains, which is necessary for induction of long-term potentiation (LTP) and synaptic strengthening by mature BDNF [54, 352] (Fig. 7, BOX D). Studies by Mizui et al. further revealed that cleaved propeptide of BDNF (pBDNF) can be independently secreted in the activity-dependent manner to facilitate LTD [353]. Strikingly, the propeptide containing the naturally occurring pBDNF-Val66Met mutation, which is associated with memory impairment and predicts cognitive decline in AD patients [37–39], binds to SorCS2 with a greater affinity than pBDNF-WT [139]. While SorCS2 binding to pBDNF-WT abolishes LTD [353], the interaction with the pBDNF-Val66Met abolishes LTD as it induces Rac1 downregulation followed by the loss of Trio-positive dendritic spines, and acute growth cone retraction [36, 139] (Fig. 7, BOX C). This regulation is followed by reduced dendritic spine density in CA1 region of hippocampus, altered prelimbic
projections and maturation of fear extinction circuitry [36, 139, 353].

So far, SorCS2 has not been studied in context of the amyloidogenic pathways. However, its multiple activities in neuronal wiring, synapse dynamics, neurotransmission, and synaptic plasticity governed by proNT-SorCS2-p75NTR and BDNF-SorCS2-TrkB signaling and by trafficking of neurotransmitter receptors and transporters, clearly demonstrate the critical role of SorCS2 in neuronal integrity and functionality. Although disturbances in SorCS2 increase neuronal vulnerability [344] and may precipitate earlier AD onset and propel disease progression for those at risk, functional studies are required to address whether SorCS2 may also directly impact on amyloid and Tau biology.

**SorCS3 biology and its role in AD**

Despite very limited knowledge about the molecular function of SorCS3, there is substantial evidence for its implications in AD. Similarly to SorCS1 and -2, SorCS3 exhibits spatiotemporal expression during development. In the adulthood, SorCS3 is expressed across the brain, with the highest expression in the CA1 region of hippocampus and in cerebral cortex [121, 122]. SorCS3 mostly localizes at the plasma membrane where it binds its ligands. Using single-particle cryogenic electron microscopy at neutral pH, Dong et al. recently suggested that human SorCS3 exists mostly as a dimer since they observed 79% of dimer particles compared to 21% of monomer particles [156]. Interestingly, SorCS3 monomer contained 10CC domain in different orientation than the dimers. They detected three different conformations of the dimers, and suggested that SorCS3 exhibits dynamic conformational changes, which differed from SorLA and SorCS2, especially in the possible ligand-binding features. However, this structural study is still quite preliminary.

SorCS3 interacts with its binding partners even prior to its maturation by propeptide cleavage [136]. The SorCS3 cytoplasmic tail is responsible for its intracellular trafficking as it navigates SorCS3 into dendrites and to a lower extent also into axons [122] (Fig. 8). The major function of SorCS3 is to control synaptic structure and function, via binding of scaffold proteins and controlling glutamate receptor trafficking [354, 355]. However, SorCS3 involvement in neurotrophin signaling has been proposed [136, 144]. In 2013, Reitz et al. described for the first time that SorCS3 is genetically associated to AD (12 SNPs). An epistatic analysis of the AD cohort revealed a strong interaction of SORCS3 mutations with those in SORCS2 (24 SNP pairs) and SORCS1 (8 SNP pairs). These mutations were all located in introns 1 and 2, thus the introns contiguous to the exons encoding the ligand-binding VPS10 domain (similarly to SNPs found in SORCS1 and SORCS2) [84]. Further, a recent whole genome sequence analysis of a multiethnic cohort comprising 11,000 women, found a strong genome-wide significant association between SORCS3 and dementia with an odds-ratio of no less than 4.4. Transcriptome analysis confirmed that SorCS3 expression is indeed substantially decreased in the context of AD [356]. These studies found that SorCS3 is consistently downregulated in AD [84, 357]. Recently, the Psychiatric Genomic Consortium identified SORCS3 as a shared top-risk gene across 8 different psychiatric disorders highlighting the pleiotropic though unclear function of SorCS3 in healthy and diseased human brain [90]. This is interestingly given a GWAS analysis from a Han Chinese cohort of AD patients with major depressive disorder further identified 675 SNPs in SORCS3 gene, thus bridging these two commonly comorbid disorders [358, 359] with one risk factor [90, 360]. In the following paragraphs, we will discuss the direct and indirect functional links of SorCS3 to AD.

**SorCS3 interactions in amyloidogenic cascade**

Ni et al. found a differential expression of SORCS3 in AD brains when comparing hippocampus, entorhinal cortex, frontal cortex, and temporal cortex [360]. Additionally, Reitz et al. showed that expression of three SORCS3 exons (exons 10, 17 and 21) is reduced in the amygdala of AD patients. In contrast, the occipital lobe and cerebellum that also express SORCS3 were unaffected by the disease [84]. The authors proposed that SorCS3 is involved in the amyloidogenic pathway by regulating the activity of γ-secretase and APP processing. Indeed, overexpression of SorCS3 leads to downregulation of γ-secretase activity, whereas SorCS3 knock-down causes an increase in γ-secretase processing of APP [84] (Fig. 8, BOX B). A recent study by Hermey et al. investigated SorCS3 expression in specific brain regions during healthy aging and after amyloidosis. They compared SorCS3 expression in aging wild-type mice with APP/PS1 mice that model AD, and develop Aβ plaque within the first year. They found that amyloid plaques formation, but not aging, reduces SorCS3 expression in the frontal cerebral cortex, with no change in the hippocampus [101]. These data suggest that the AD pathogenesis is associated with impaired SorCS3 activity in a brain region-specific manner.

**SorCS3 in AD-related neurotrophin signaling and synaptic transmission**

During development, SorCS3 acts as a downstream effector of Transcription factor T-box brain1 (Tbr1) expression that restricts dendritic projections towards their synaptic targets [361] (Fig. 8, BOX A). Immature as well as cleaved SorCS3 receptor can bind proNGF and NGF.
in vitro but the functional consequences have not been explored [136]. However, a recent paper by Zhang et al. suggests that SorCS3, as opposed to Sortilin and SorCS2, prevents p75NTR signaling by increasing its internalization and transport to lysosomes for degradation [362]. The implications for proNGF signaling, however, were not studied. As proposed for SorCS1, SorCS3 can physically interact with TrkB which abrups BDNF-dependent TrkB activity in the hypothalamus, and likely contributes to energy metabolism balance [144] (Fig. 8, BOX C).

Unfortunately, as for SorCS1, the functional impact and mechanistic insight of this crosstalk are not clear since only mice devoid in both Sorcs1 and Sorcs3 were studied. However, TrkB was enriched in synaptosomes in brain extracts of the double Sorcs1; Sorcs3 knockout mouse while it was reduced in sorting vesicles. Accordingly, BDNF-induced TrkB phosphorylation was stronger in cultured cortical neurons from mice lacking both receptors [144]. Hence, the VPS10p-D receptors jointly modulate all key functions of BDNF signaling. Strikingly, they do so by...
controlling specific steps in TrkB trafficking (for Sortilin also demonstrated with TrkA and TrkC [142]). Sortilin enables the anterograde transport of TrkB from the soma along axons to the synapse [142]. SorLA can do the same but it also facilitates its retrograde transport, potentially in signaling endosomes [143]. Locally at the synapse, SorCS2 takes over the TrkB from Sortilin and SorLA to target it from extrasynaptic sites to postsynaptic densities [54]. In marked contrast to the rest of the family, SorCS1 and/or SorCS3 impedes BDNF signaling by removing TrkB from the synapse [144]. In all, the receptors jointly control and fine-tune BDNF signaling; a key regulator of neuronal integrity and vulnerability.

Aside from these observations, SorCS3 relations to neurotrophic signaling and plasticity remain unknown. Recent studies highlighted SorCS3 as an important regulator of synaptic events in excitatory neurons but with only minimal impact on the inhibitory input [354, 355]. Moreover, SorCS3 deficient mice exhibit loss of NMDAR and mGluR-dependent LTD in the hippocampal CA1 region, while LTP is preserved. These mice have no sign of brain atrophy but respond to repetitive stimulation with synaptic facilitation and reduced synaptic depression; a phenotype that progressively worsened as the animals aged [355]. This is particularly interesting as SorCS3 expression is regulated by neuronal activity including LTP [124] and seizures [125]. Fear conditioning enhances Sorcs3 expression by no less than 170-fold in hippocampal engram cells arguing that SorCS3 signaling and/or sorting contributes to memory formation and consolidation [126]. Indeed, studies using Sorcs3 KO mice reported that the animals exhibited impaired spatial learning but increased fear extinction [354]. Interestingly, protein levels of PSD95, AMPA receptors, NMDA receptors, mGluR5, p75NTR, and TrkB are not changed in postsynaptic density fraction extracted from hippocampi of Sorcs3 KO mice [354]. However, Breiderhoff et al. showed that SorCS3 crosstalks with some synaptic proteins. SorCS3 localizes at the postsynaptic density where it binds PSD95 via its putative PDZ domain binding motif in its cytoplasmic domain [354]. The authors also proposed that SorCS3 interacts with an adapter molecule PICK1 by which it controls the necessary removal of the AMPA receptors from the postsynaptic side [354], similarly to SorCS1 [133]. This study was further supported by electrophysiological observations that LTD deficiency in CA1 region is age-dependent, and that the loss of SorCS3 impacts on AMPA receptors mobility [355]. SorCS3 actions at postsynapse of excitatory neurons during memory formation are depicted in (Fig. 8, BOX D).

Given the genetic association to AD and the important functions of SorCS3 in APP processing, synaptic transmission, and synaptic retraction of excitatory neurons involved in learning and memory, additional studies are merited to examine its role in the context of AD. SorCS3 remains the least studied of the VPS10 p-D receptors. Future studies should thus: 1) Determine SorCS3 binding partners in amyloidogetic pathways and synaptic events, and 2) describe the molecular mechanisms by which SorCS3 regulates synaptic transmission in the healthy and AD brain. Moreover, SorCS3 possible interaction with the neurotrophic signaling deserves more attention as the rest of this receptor family serves critical functions in neurotrophin-dependent neuronal survival and death.

**Therapeutic perspectives of VPS10p-D receptors in AD**

It remains unclear whether certain neurons in AD brains become vulnerable mostly due to intrinsic or extrinsic factors. The largest therapeutic potential used to lie within blocking the amyloidogetic cascade, and/or dissolving the amyloid plaques and Tau-containing tangles. Unfortunately, the current strategies are inefficient and do not stop the disease progression. In this review, we illustrated that the AD pathogenesis has been tightly connected with impaired activity of VPS10p-D receptors in neurons. However, not much is known about VPS10p-D receptors signaling in the context of intercommunication between cell types such as microglia-neuron, a feature largely implicated in AD. Microglia are non-neuronal cells that support neurons by secreting trophic factors and performing phagosytic clearance during synapse remodeling and tissue repair. Together with astrocytes they are responsible for ApoE production which controls the deposition and clearance of Aβ peptides. With AD progression and increased Aβ accumulation, activated microglia compromise their phagocytic abilities, alter their secretome, and mediate chronic neuroinflammation leading to synaptic loss and AD neurodegeneration. The possession of ApoE4 allele triggers and sustains the microglia-driven neuroinflammation. Enhancing phagocytosis and decreasing neuroinflammation in AD patients has become a new therapeutic target, even though this cell communication remains a black box [363, 364]. Since neuronal VPS10p-D receptors closely and diversely interact with ApoE, Aβ and synaptic proteins, understanding the molecular mechanisms involved in this intercellular communication is key when targeting AD pathogenesis. The importance of VPS10p-D receptors in neurotrophic signaling during CNS development and homeostasis also possesses a high translational value. Current advances in regenerative medicine show that reactivating the developmental features related to neurotrophic signaling during trauma and neuroinflammation promotes healing and improves the cognitive decline as it provides substantial functional recovery [365]. The potential of cell
replacement therapies in AD represents a symptomatic solution with limited efficacy due to the broad spread of neurodegeneration. However, recent studies uncovered that elevating the neurotrophin levels (such as BDNF, NGF and GDNF) in AD mice supports neuronal integration of grafted cells into the circuits, which improves the cognitive deficits [366, 367]. Recent work from Choi et al. combined pharmacological and genetic approaches to elevate BDNF levels in the AD mouse model (5xFAD) to trigger adult neurogenesis in hippocampus. Indeed, this strategy improved cognitive performance of the mice [368]. Similarly, conditional BDNF delivery provided by astrocytes rescued dendrite outgrowth, neuronal connectivity and memory deficits in another AD study [369]. As boosting the BDNF concentration increases the neuroprotective levels of SorLA [137], such therapy could provide a relief of the AD symptoms.

Neurotrophins and Trk receptors facilitate a vast spectrum of functions in the CNS, and thus they represent a difficult therapeutic target. We therefore suggest that novel pharmacological interventions should instead aim for their binding partners, the VPS10p-D receptors, because they control more defined processes. Promoting the interaction between Trk receptors and VPS10p-D receptors might have positive effects on neurotrophin-dependent cell survival. Sortilin KO mice are resistant to acute and senescent neurodegeneration [53]. Therefore, drug discovery of Sortilin antagonists that block the ability of Sortilin interaction with p75NTR also represents a novel way of intervention against progressive cell death in AD. This approach has been proven functional for treating another neurodegenerative disease, frontotemporal dementia (FTD) which exhibits impaired Sortilin-progranulin signaling axis [272, 370]. Currently, there is an ongoing FTD immunotherapy entering Phase 3 clinical trials that uses a monoclonal anti-human Sortilin antibody called AL001 (Identifier: NCT04374136) [371]. If approved, this treatment could be expanded to AD patients.

Indeed, the various molecular interactions of VPS10p-D receptors in AD-related cell communication, their functional involvement in amyloidogenic pathways, and most importantly, their genetic links to AD identify these receptors as highly promising clinical targets for future advances in AD diagnostics and therapy.

**Conclusions**

Several human genetic and functional studies have repeatedly linked the VPS10p-D receptor family to AD, and to its pathophysiological features including accumulation of extracellular Aβ. Importantly, simultaneous deregulation of multiple members of this family has an epistatic effect on the AD onset. For example, both SorLA, Sortilin, and SorCS1 play a major role in controlling APP trafficking, but they guide the precursor to different subcellular destinies. Similarly, SorLA directly interacts with Aβ, whereas the other receptors influence amyloid accumulation by acting in its metabolic processing. Impaired signaling of VPS10p-D proteins also leads to altered ratio between the amount of immature and mature neurotrophic factors thereby altering synaptic plasticity and neuronal cell fate, common features of AD. Last but not least, VPS10p-D receptor family has been linked to major depressive disorder, prion-like infections, and diabetes mellitus, thus diseases that often accompany AD diagnosis. At present, we still have poor understanding about the precise molecular mechanisms by which these receptors signal in healthy and AD brains. Nevertheless, it is indeed clear that the versatility of VPS10p-D receptors and their broad molecular interactions with AD-related pathways can help explaining the AD diversity and its comorbidities. We therefore expect that this exciting field will soon escalate, and lead to uncovering many new diagnostic and therapeutic possibilities for AD patients in the future, in particular with focus on SorLA, Sortilin, and SorCS1/3.

**Abbreviations**

AD: Alzheimer’s disease; ADAM9/10/11/17: Alpha secretase ADAM-metalloproteinase domain 9/10/11/17; AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid AMPA glutamate receptor; AP-1/AP-2: Adaptor protein complex 1/2; APOE: Apolipoprotein E; APP: Amyloid-beta precursor protein; Aβ: Amyloid beta; AβO: Cytotoxic amyloid beta oligomers; BACE1: Beta-site amyloid precursor protein cleaving enzyme secretase 1; BDNF: Brain-derived neurotrophic factor; BDNF-Val66Met: Bran-derived neurotrophic factor carrying a substitution of Valine with Methionine; BFCN: Basal forebrain cholinergic neuron; BMP: Bone morphogenetic protein; CASP3: Caspase 3; CNS: Central nervous system; CSF: Cerebral spinal fluid; EAAT3: Excitatory amino acid transporter 3; EOAD: Early-onset Alzheimer’s disease; EphA4: Echin A-type A 4 receptor; FTD: Frontotemporal dementia; GDNF: Glial cell line-derived neurotrophic factor; GFRα1: GDNF Family Receptor Alpha 1; GGA: Golgi-localized gamma-ear-containing ARF-binding protein; GRN: Granulin; GSK3B: Glycogen synthase kinase-3 beta; GWAS: Genome-wide association studies; HSP12A: Heat shock protein 12A; iPS cells: Induced pluripotent stem cells; IR: Insulin receptor; LDL: Low-density lipoprotein; LOAD: Late-onset Alzheimer’s disease; LTD: Long-term depression; LTP: Long-term potentiation; mGlur5: Metabotropic glutamate receptor 5; NGF: Nerve growth factor; NMDAR: N-methyl-D-aspartate receptor; NT3/4: Neurotrophin 3/4; p75NTR: Neurotrophin receptor denoted p75; PI3K: 1-3: Rac-p21-activated kinases 1 to 3; pBDNF: Propeptide of BDNF (after cleavage of proBDNF); PCK59: Proprotein convertase subtilisin/kexin type 9; PGRN: Progranulin; PICK1: Protein interacting with C kinase 1; PNS: Peripheral nervous system; proBDNF: Precursor of brain-derived neurotrophic factor; proNGF: Precursor of nerve growth factor; proNTs: Prolactin neurotrophins; PrPSc: Scrapie prion protein; SORL1-38b: Splice variant of SORL1 containing novel exon 38b; sSorLA: Soluble SorLA; Tau: Hyperphosphorylated; TAT: Sortilin-related receptor 1; TRKA: Trans-Golgi network; TNFα: Tumor necrosis factor alpha; TrkA/B/C: TrkA/B/C tyrosine kinases A/B/C;
References

1. 2020 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2020;16(3):391-460. https://doi.org/10.1002/alz.12068.

2. Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, Cummings J, van der Flier WM. Alzheimer’s disease. Lancet. 2017;131:13–23.

3. Wang J, Gu BJ, Masters CL, Wang Y-J. A systemic view of Alzheimer disease — insights from amyloid-β metabolism beyond the brain. Nat Rev Neurosci. 2017;18:1349–56.

4. Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer’s disease. Nat Rev Neurol. 2013;9:106–18.

5. Parashar M, Smolen M, Mutus N, et al. APOE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–13.

6. Scrafton JA, Perneczky A, et al. Ethics approval and consent to participate. Not applicable.

7. Deane R, Sagare A, Hammad K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV. apoE isoform-specific disruption of amyloid beta peptide clearance. J Clin Invest. 2008;118:4002–13.

8. Dorey E, Barnji-Mirza M, Najem D, LiY, Liu H, Callaghan D, Walker D, Lue LF, Stanimirovic D, Zhang W, Apolipoprotein E isoforms Differentially Regulate Alzheimer’s Disease and Amyloid-beta-Induced Inflammatory Pathway Is Dysregulated by APOE4 Expression in Vivo. Front Neurosci. 2017;11:702.

9. Nouril T, Angulo SL, Khan U, Chen Q, Figueroa HY, Emrani S, Grinberg LT, Rojas JC, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523–7.

10. Chen Y, Durakoglugil MS, Xian K, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA. 2010;107:12011–6.

11. Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, Berg S, Fiske A, Pedersen NL. Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry. 2006;63:168–74.

12. Hoogmartens J, Casaca R, Van Broeckhoven C. Insight into the genetic etiology of Alzheimer’s disease: A comprehensive review of the role of rare variants. Alzheimers Dement. 2021;13:12155.

13. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, Seelock J, Karlsson IK, Hägg S, Athanasiou L, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019;51:404–13.

14. Bellenguez C, Kujal F, Jansen IE, Kleinendam L, Moreno-Grau S, Amin N, Naj AC, Campos-Martín R, Grenier-Boley B, Andrade V, et al. New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet. 2022;54:412–36.

15. Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Dampote V, Naj AC, Roland A, Vonsksay M, van der Lee SJ, Amlo-Wolf A, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates AB, tau, immunity and lipid processing. Nat Genet. 2019;51:14–30.

16. Ridge PG, Hoyt KB, Boehme K, Mukherjee S, Crane PK, Haines JL, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD, Kauwe JSK. Assessment of the genetic variance of late-onset Alzheimer’s disease. Neurobiol Aging. 2016;41.e120-41.e2200.

17. Nixon RA. Amyloid precursor protein and endosomal-lysosomal dysfunction in Alzheimer disease: inseparable partners in a multifactorial disease. FASEB J. 2017;31:1279–43.

18. Wang X, Huang T, Bu G, Xu H. Dysregulation of protein trafficking in neurodegeneration. Mol Neurodegener. 2014;9:31.

19. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neuro. 2013;9:106–18.

20. Nouril T, Peng KY, Ashok A, Dillman AA, Figueroa HY, Apuzzo J, Ambat J, Levy E, Cookson MR, Mathews PM, Duff KE. The Endosomal-Lysosomal Pathway Is Dysregulated by APOE4 Expression in Vivo. Front Neurosci. 2017;11:702.

21. Nouril T, Angulo SL, Khan U, Ashok A, Chen Q, Figueroa HY, Emrani S, Liu L, Herman M, Baret et al. Neuroonal hyperactivity due to loss of inhibitory tone in APOE4 mice lacking Alzheimer’s disease-like pathology. Nat Commun. 2017;8:14646.

22. Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523–7.

23. Chen Y, Durakoglugil MS, Xian K, Herz J. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling. Proc Natl Acad Sci USA. 2010;107:12011–6.

24. Conroy JN, Coulson EJ. High-affinity TrkA and p75 neurotrophin receptor complex: A twisted affair. J Biol Chem. 2002;278:105568.

25. Scott-Solomon E, Kuruvilla R. Mechanisms of neurotrophin trafficking via TrkB receptors. Mol Cell Neurosci. 2018;91:25–33.

26. Phillips HS, Hains JM, Aramini M, Laramée GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuro. 1991;7:695–702.

27. Ginsberg SD, Malek-Ahmadi MH, Allidred MJ, Chen Y, Chen K, Mao MV, Counts SE, Mufson EJ. Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neurtic plaque and neurofibrillary tangle pathology. Neurobiol Dis. 2019;132:104540.
32. Lee J, Fukumoto H, Orne J, Klucken J, Raju S, Vanderburg CR, Irizarry MC, et al. Molecular Neurodegeneration (2022) 17:74.
34. Girotra P, Behl T, Sehgal A, Singh S, Bungau S. Investigation of the Notaras M, van den Buuse M. Neurobiology of BDNF in fear memory, Giza JI, Kim J, Meyer HC, Anastasia A, Dincheva I, Zheng CI, Lopez Lim YY, Hassenstab J, Cruchaga C, Goate A, Fagan AM, Benzinger TL, 40. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked 43. Wang ZH, Xiang J, Liu X, Yu SP, Manfredsson FP, Sandoval IM, Wu S, 45. Xia Y, Wang ZH, Liu P, Edgington-Mitchell L, Liu X, Wang XC, Ye K. TrkB
46. Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer
48. Wang YL, Chio CC, Kuo SC, Yeh CH, Ma JT, Liu WP, Lin MT, Lin KC, Chang
50. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science (New York, NY). 2001;294:1945–8.
51. Costa RO, Perestrello T, Almeida RD. PROneurotrophins and CONSequences. Mol Neurobiol. 2018;55:2934–51.
52. Nykaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen K, C Kleineman J, Schwartz E, Willnow TE, et al. SorCS1 is essential for proNGF-induced neuronal cell death. Nature. 2004;427:843–8.
53. Jansen P, Giehl K, Nyengaard JR, Teng K, Liuqibundo S, Snoegaard SS, Breiderhoff T, Gotthardt M, Lin F, Elers A, et al. Roles for the pro-neurotrophin receptor sorcin1 in neuronal development, aging and brain injury. Nat Neurosci. 2007;10:1449–57.
54. Glerup S, Bolcho U, Molgaard S, Boggild S, Vaeger CB, Smith AH, Nieto-Gonzalez JL, Ovesen PL, Pedersen LF, Fjorback AN, et al. SorC2 is required for BDNF-dependent plasticity in the hippocampus. Mol Psychiatry. 2016;21:740–51.
55. Deindhart K, Kim T, Spellman DS, Mains RE, Epper BA, Neubert TA, Chao MV, Hempstead BL. Neuronal growth cone retraction relies on proneurotrophin receptor signaling through Rac. Sci Signal. 2011;4:ra82.
56. Woo NH, Teng HK, Sajo CJ, Chiurattini C, Pang PT, Milner TA, Hempstead BL. B. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci. 2005;8:1696–77.
57. Fleitas C, Pinol-Ripoll G, Marfull P, Rocandio D, Ferrer I, Rampon C, Egea J, Espinet C. proBDNF is modified by advanced glycation end products in Alzheimer’s disease and causes neuronal apoptosis by inducing p75 neurotrophin receptor processing. Mol Brain. 2018;11:68.
58. Michalski B, Fahnestock M. Pro-brain-derived neurotrophic factor is decreased in parietal cortex in Alzheimer’s disease. Brain Res Mol Brain Res. 2003;111:148–54.
59. Mufson EJ, Counts SE, Fahnestock M, Ginsberg SD. Cholinoptrophic molecular substrates of mild cognitive impairment in the elderly. Curr Alzheimer Res. 2007;4:340–50.
60. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 2005;93:1412–21.
61. Fahnestock M, Garzon D, Holmes RMD, Michalski B. Neurotrophic factors and Alzheimer’s disease: are we focusing on the wrong molecule? J Neurotransm Suppl. 2002;62:241–52. https://doi.org/10.1007/978-3-7091-6139-5_22.
62. Fahnestock M, Michalski B, Xu B, Couglin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer’s disease. Mol Cell Neurosci. 2001;18:210–20.
63. Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol. 2004;63:641–9.
64. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, Fritz J, Lah J, Ginsberg SD, Wuu J, Scheff SW. Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol. 2012;71:1018–29.
65. Counts SE, He B, Prout JG, Michalski B, Farotti L, Fahnestock M, Mufson EJ. Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease. Curr Alzheimer Res. 2016;13:800–8.
66. Tria C, Ruberti F, Canu N. NGF and the Amyloid Precursor Protein in Alzheimer’s Disease: From Molecular Players to Neuronal Circuits. Adv Exp Med Biol. 2021;1331:145–65.
67. Cuello AC, Bruno MA, Bell KF. NGF–cholinergic dependency in brain aging, MCI and Alzheimer’s disease. Curr Alzheimer Res. 2007;4:351–8.
68. Tria C, Ruberti F, Canu N. NGF and the Amyloid Precursor Protein in Alzheimer’s Disease. From Molecular Players to Neuronal Circuits. Adv Exp Med Biol. 2021;1331:145–65.
69. Cuello AC, Bruno MA, Bell KF. NGF–cholinergic dependency in brain aging, MCI and Alzheimer’s disease. Curr Alzheimer Res. 2007;4:351–8.
71. Chakravarty B, Menard M, Ito S, Gaudet C, Dal Pra I, Armato U, Whitfield J. Hippocampal membrane-associated p75NTR levels are increased in Alzheimer's disease. J Alzheimers Dis. 2012;30:675–84.

72. Jiao SS, Bu XL, Liu YH, Wang QH, Liu CH, Yao XQ, Zhou XF, Wang YJ. Differential levels of p75NTR ectodomain in CSF and blood in patients with Alzheimer's disease: a novel diagnostic marker. Transl Psychiatry. 2015;5:e650.

73. Yaq XQ, Jiao SS, Saaidipour K, Zeng F, Wang QH, Zhu C, Shen LL, Zeng GH, Liang CR, Wang J, et al. p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer's disease. Mol Psychiatry. 2014;20:1301–10.

74. Mufson EJ, Li JM, Sobreviela T, Kordower JH. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. Neuronreport. 1996;8:25–9.

75. Dubus P, Fauchex B, Boissière F, Groppi A, Vital C, Vital A, Aged Y, Hirsch EC, Merlio JP. Expression of Trk isoforms in brain regions and in the striatum of patients with Alzheimer's disease. Exp Neurol. 2000;165:285–94.

76. Hock C, Heese K, Muller-Spahn F, Hulleke C, Rosenberg C, Otten U. Decreased trkA neurotrophin receptor expression in the parietal cortex of patients with Alzheimer's disease. Neurosci Lett. 1998;241:151–4.

77. Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem. 2008;106(5):275–87.

78. Yi C, Goh KY, Wong LW, Ramanujan A, Tanaka K, Sajukumar S, Ibañez CF. Inactive variants of death receptor p75(NTR) reduce Alzheimer's neuropathology by interfering with APP internalization. EMBO J. 2021;40:e109067.

79. Qian L, Milne MR, Shepheard S, Rogers ML, Medeiros R, Coulson EJ. Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell. 2019;179:1469–1482.e1411.

80. Lane RF, Cadde TB, Zwizinski CW, Lah JJ, Golde TE. SorLA, SorCS1b, and SorLA/Vps10p sorting receptors, are novel gamma-secretase substrates. Mol Neurodegener. 2006;1:3.

81. Lane RF, Raines SM, Steele JW, Ehrlich ME, Lah JA, Small SA, Tanzi RE, Attie AD, Gandy S. Diabetes-associated SorLA regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci. 2010;30:15110–5.

82. Carlo AS, Gustafsen C, Mastrobuoni G, Nielsen MS, Burgert T, Hartl D, Rohe M, Nykjaer A, Herz J, Heeren J, et al. The pro-neurotrophin receptor sortin is a major neuronal apollipoprotein E receptor for catabolism of amyloid-beta peptide in the brain. J Neurosci. 2013;33:3558–70.

83. Philtjens S, Van Morssevele S, van der Zee J, Wauters E, Dillen L, Vandenbulcke M, Vandenbergh R, Ivanouiev A, Sieben A, Willems C, et al. Rare nonsynonymous variants in SORL1 are associated with increased risk for late-onset Alzheimer's disease. Neureport. 2018;29:181.e183-181.e110.

84. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, vom Arim CA, Breiderhoff T, Jansen P, Wu X, et al. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci USA. 2005;102:13461–6.

85. Huang TY, Zhao Y, Jiang LL, Li X, Liu Y, Sun Y, Pina-Crespo JC, Zhu B, Masliyah E, Willnow TE, et al. SorLA attenuates EphA4 signaling and amyloid beta-induced neurodegeneration. J Exp Med. 2017;214:3669–85.

86. Gustafsen C, Glorup S, Paallesen LT, Olsen D, Andersen OM, Nykjaer A, Madsen P, Petersen CM. SorLA and SorLA display distinct roles in processing and trafficking of amyloid precursor protein. J Neurosci. 2013;33:66–71.

87. Schmidt V, Baum K, Lao A, Rataieckach K, Schmitz T, Teichmann A, Wiesner B, Petersen CM, Nykjaer A, Wolf J, et al. Quantitative modelling of amyloidogenic processing and its influence by SorLA in Alzheimer's disease. EMBO J. 2012;31:187–200.

88. Mehmedbasic A, Christensen SK, Nilsson J, Ruetschi U, Gustafsen C, Poulsen AS, Rasmussen RW, Fjorback AN, Lanson G, Andersen OM. SorLA complement-type repeat domains protect the amyloid precursor protein against processing. J Biol Chem. 2015;290:3359–76.

89. Andersen OM, Schmidt V, Spoelgen R, Gilemam J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, Hyman BT, et al. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry. 2006;45:2618–28.

90. Hermy G, Hofmeister-Ulrich SA, Merz B, Gross D, Kuhl D, Kiris S. Amyloidosis causes downregulation of SorLA, SorCS1 and SorCS3 expression in mice. Biol Chem. 2019;400(9):1181–9.

91. Nunes AF, Amaral JD, Lo AC, Fonseca MB, Viana RJ, Callaerts-Vegh Z, D’Hooge R, Rodrigues CM. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/P51 mice. Mol Neurobiol. 2012;45:440–54.

92. Finan GM, Okada H, Kim TW. BACE1 retrograde trafficking is uniquely regulated by the cytoplasmic domain of sortin. J Biol Chem. 2011;286:12602–16.

93. Ruan CS, Liu J, Yang M, Saaidipour K, Zeng YQ, Liao H, Wang YJ, Bobrovskaya L, Zhou XF. SorLA inhibits amyloid pathology by regulating non-specific degradation of APP. Exp Neurol. 2018;299:75–85.

94. Yang M, Virasamy B, Vaiyagar SL, Lim Y, Saaidipour K, Wang YJ, Han YC, Zhong JH, Morales CR, Zhou XF. The intracellular domain of sortin interacts with amyloid precursor protein and regulates its lysosomal and lipid raft trafficking. PLoS ONE. 2013;8:e63049.

95. Lane RF, Steele JW, Cai D, Ehrlich ME, Attie AD, Gandy S. Protein sorting motifs in the cytoplasmic tail of SorCS1 control generation of Alzheimer’s amyloid-beta peptide. J Neurosci. 2013;33:7095–107.

96. Hermy G, Schmidt N, Bluhm B, Mensching D, Ostermann K, Rupp C, Kuhl D, Kiris S. SorCS1 variants and amyloid precursor protein (APP) are
co-transported in neurons but only SorCS1c mediates anterograde APP transport. J Neurochem. 2015;135:60–75.

108. Reitz C, Tokuhiko S, Clark LN, Conrad C, Vonsattel JP, Hazrati LN, Palotas A, Lantigua R, Medrano M, Jiménez-Velázquez I, et al. SorCS1 alters amyloid precursor protein processing and variants may increase Alzheimer's disease risk. Ann Neurol. 2011;69:647–64.

109. Kitago Y, Nagae M, Nakata Z, Yagi-Lutsumi M, Takagi-Niidome S, Mihara E, Nogi T, Kato K, Takagi J. Structural basis for amyloidogenic peptide recognition by sorLA. Nat Struct Mol Biol. 2015;22:199–206.

110. Yajima R, Tokutake T, Koyama A, Kasuga K, Tezuka T, Nishizawa M, Caglayan S, Takagi-Niidome S, Liao F, Carlo AS, Schmidt V, Burgert T, Saadipour K, Yang M, Lim Y, Georgiou K, Sun Y, Keating D, Liu J, Wang Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Hermey G, Sjogaard SS, Petersen CM, Nykjaer A, Gliemann J. Tumour Yamazaki H, Bujo H, Kusunoki J, Seimiya K, Kanaki T, Morisaki N, Evans SF, Irmady K, Ostrow K, Kim T, Nykjaer A, Saftig P, Blobel C, Hempstead BL, Bracken C. Val66Met polymorphism of BDNF alters prodomain processing into an Apoptotic Two-Chain Receptor in Peripheral Glia. Neuron. 2014;82:1074–87.

111. Hampe W, Rezgouli M, Hermey G, Nykjaer A, Schaller HC. Expression of SorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci. 2006;26:418–28.

112. Hermey G, Sjogaard SS, Petersen CM, Nykjaer A, Gilemman J. Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J. 2006;395:285–93.

113. Yamazaki H, Bujo H, Jiménez-Velázquez I, et al. SORCS1 alters recognition by sorLA. Nat Struct Mol Biol. 2015;22:199–206.

114. Evans SF, Irmady K, Ostrow K, Kim T, Nykjaer A, Saftig P, Blobel C, Hempstead BL, Bracken C. Val66Met polymorphism of BDNF alters prodomain processing into an Apoptotic Two-Chain Receptor in Peripheral Glia. Neuron. 2014;82:1074–87.

115. Rohe M, Synowitz M, Glass R, Paul SM, Nykjaer A, Willnow TE. Brain-derived neurotrophic factor reduces amyloidogenic processing through control of SORLA gene expression. J Neurosci. 2009;29:15472–8.

116. Yoneyama H, Irmady K, Ostrow K, Kim T, Nykjaer A, Saftig P, Blobel C, Hempestand BL. Neuronal brain-derived neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal degradation. J Biol Chem. 2011;286:29556–67.

117. Navarro V, Vincent JP, Mazella J. Shedding of the luminal domain of the neurotensin receptor-3/sorilin in the HT22 cell line. Biochim Biophys Acta. 2002;159:760–4.

118. Hermans-Borgmeyer I, Hampe W, Schinke B, Methner A, Nykjaer A, Susens UJ, Fenger U, Herbart BH, Schaller HC. Unique expression pattern of a novel mosaic receptor in the developing cerebral cortex. Mech Dev. 1998;70:65–76.

119. Hermans-Borgmeyer I, Hermey G, Nykjaer A, Schaller C. Expression of the 100-kDa neurotensin receptor sorilin during mouse embryonal development. Brain Res Mol Brain Res. 1999;65:216–9.

120. Hermey G, Plasth N, Hubner CA, Kuhl D, Schaller HC, Hermans-Borgmeyer I. The three sorCS genes are differentially expressed and regulated by synaptic activity. J Neurochem. 2004;88:1470–6.

121. Oetjen S, Mahlke C, Hermans-Borgmeyer I, Hermey G. Spatiotemporal control of APP transport. J Neurochem. 2015;135:60–75.

122. Oetjen S, Mahlke C, Hermans-Borgmeyer I, Hermey G. The three sorCS genes are differentially expressed and regulated by synaptic activity. J Neurochem. 2004;88:1470–6.
146. Munck Petersen C, Nielsen MS, Jacobsen C, Tauris J, Jacobsen L, Glie-
salasova
147. Nielsen MS, Jacobsen C, Olivecrona G, Gliemann J, Petersen CM.
148. Hermey G, Keat SJ, Madsen P, Jacobsen C, Petersen CM, Gliemann J.
149. Whittle AJ, Jiang M, Peirce V, Relat J, Virtue S, Ebinuma H, Fukamachi
150. Stupack J, Xiong XP, Jiang LL, Zhang T, Zhou L, Campos A, Ranscht
151. Ogawa K, Ueno T, Iwasaki T, Kujiraoka T, Ishihara M, Kunimoto S,
152. Januliene D, Manavalan A, Ovesen PL, Pedersen KM, Thirup S, Nykjaer A,
153. Malik AR, Willnow TE. VPS10P Domain Receptors: Sorting Out Brain
154. Yabe-Wada T, Matsuba S, Unno M, Onai N. Crystal structure of the
155. Leloup N, Lossl P, Meijer DH, Brennich M, Heck AJR, Thies-Weesie DME,
156. Zhang X, Wu C, Song Z, Sun D, Zhai L, Liu C. Cryo-EM structures reveal
157. Holstege H, van der Lee SJ, Hulsman M, Wong TH, van Rooij JG, Weiss M,
158. Raghavan NS, Brickman AM, Andrews H, Manly JJ, Schupf N, Lantigua
159. Louwersheimer E, Cohn-Hokke PE, Pijnenburg YA, Weiss MM, Sistermans
160. Fernández MV, Black K, Carrell D, Saef B, Budde J, Deming Y, Howells B,
161. Gómez-Tortosa E, Ruggiero M, Sainz MJ, Villarejo-Galende A, Piere-Jure-
zynska C, Venegas Pérez B, Ordsás C, Aguero P, Guerrero-López P, Pérez
162. Korjupa A, Kruger K, Kovulovou S, Pylkäs K, Moilanen V, Helsalimi S,
163. Whittle AJ, Jiang M, Peirce V, Relat J, Virtue S, Ebinuma H, Fukamachi
164. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stem Y, Rogaeva E,
165. Fernández MV, Black K, Carrell D, Saef B, Budde J, Deming Y, Howells B,
166. Gómez-Tortosa E, Ruggiero M, Sanz MJ, Villarejo-Galende A, Piere-Jure-
zynska C, Venegas Pérez B, Ordsás C, Aguero P, Guerrero-López P, Pérez
167. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stem Y, Rogaeva E,
168. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stem Y, Rogaeva E,
169. Nicolas G, Charbonnier C, Bellenguez C, Grenier-Boley B, Rousseau S, Richard AC, Rovelet-Lecrux A, Le Guennec K, et al. SORL1 rare variants: a major risk factor for familial early-onset Alzheimer's disease. Mol Psychiatry. 2016;21:831-836. https://doi.org/10.1038/mp.2015.121.
170. Alvarez-Mora M, Blanco-Palmero VA, Quesada-Espinoza JF, Arteche-
lopez ARP, Llamas-Velasco S, Palma Milia C, Lezana Rosales JM, Gomez-

Page 31 of 36

Salasova et al. Molecular Neurodegeneration (2022) 17:74
183. Binkle L, Klein M, Borgmeyer U, Kuhl D, Hermey G. The adaptor protein et al. Molecular Neurodegeneration (2022) 17:74
185. Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, Schaller C, Bujo H, Levey AI, Lah JJ. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004;61:1200–5.
187. Dodson SE, Andersen OM, Karmali V, Fritz JJ, Cheng D, Peng J, Levey AI, Ma QL, Galasko DR, Ringman JM, Vinters HV, Edland SD, Pomakian J, Ikeuchi T, Hirayama S, Miida T, Fukamachi I, Tokutake T, Ebinuma. Regulated O-glycosylation of an alternatively spliced variant of SORL1 in neuronal dendrites is decreased in patients with Alzheimer’s disease. Acta Neuropathol Comm. 2021;9:43.
189. Schroeder AF, Rozemuller AJ, van der Flier WM, Scheltens P, van der Vliet WM, Hoozemans JJ. Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer’s disease correlates with pathology. Acta Neuropathol Commun. 2014;2:79.
191. Vardarajan BN, Ghami M, Khan A, Sheikh S, Cato B, Patel V, Kannan S, Kim YH, et al. Alzheimer’s vulnerable brain region relies on a distinct retromer core dedicated to endosomal recycling. Mol Psychiatry. 2020;24:857–68.
193. Murphy KK, Pasquale EB. Eph receptors, ephrins, and synaptic function. Neuroscientist. 2004;10:304–14.
195. Egea J, Nissen UV, Dufour A, Yuan M, Okada H, Honig L, Von-der-Porten E, Vassier SM, Hoozemans JJ. Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer’s disease correlates with pathology. Acta Neuropathol Commun. 2014;2:79.
197. Salasova et al. Molecular Neurodegeneration (2022) 17:74 Page 32 of 36
219. Mufson EJ, Wuu J, Counts SE, Nykjaer A. Preservation of cortical sortilin protein levels in MCI and Alzheimer’s disease. Neurosci Lett. 2010;471:129–33.

220. Zhou FQ, Jiang J, Griffith CM, Pattrylo PR, Cai H, Chu Y, Yan XX. Lack of human-like extracellular sortilin neuropathology in transgenic Alzheimer’s disease model mice and macaques. Alzheimers Res Ther. 2018;10:40.

221. Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Madsen P, Christensen EI, Nykjaer A, Gliemann J, Kasper D, Baltes J, Larsen JV, Radhakrishnan K, Geumann C, Kratzke M, Petersen Pallesen LT, Gustafsen C, Cramer JF, Petersen SV, Thirup SS, Madsen P, Yang M, Lim Y, Li X, Zhong JH, Zhou XF. Precursor of brain-derived neurotrophic factor (BDNF) interacts with protein in the rat central nervous system. J Comp Neurol. 2003;461:483–505.

222. Johnson NR, Cornillo C, Guan S, Oehler A, Becker J, Gavidia M, Carlson GA, Giles K, Prusiner SB. Evidence for sortilin modulating regional accumulation of human tau proins in transgenic mice. Proc Natl Acad Sci USA. 2017;114:E11029-e11036.

223. Nielsen MS, Madsen P, Christensen EI, Nykjaer A, Gliemann J, Kasper D, Pohlmann R, Petersen CM. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001;20:2180–90.

224. Baltes J, Larsen JV, Radhakrishnan K, Geumann C, Kratzke M, Petersen CM, Schu P. σ1B adaptin regulates adipogenesis by mediating the sorting of sortilin in adipose tissue. J Cell Sci. 2014;127:3477–87.

225. Pohlmann R, Petersen CM. The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein. EMBO J. 2001;20:2180–90.

226. Pallesen LT, Gustafsen C, Cramer JF, Petersen SV, Thirup SS, Madsen P, Petersen CM. PAK Kinases Target Sortilin and Modulate Its Sorting. Mol Cell Biol. 2020;40:e00411-19.

227. Progida C, Nielsen MS, Koster G, Bucci C, Bakke O. Dynamics of Rab7-dependent transport of sorting receptors. Traffic. 2012;13:1273–85.

228. Mari M, Bujny MV, Zeuchserner D, Geerts WJ, Griffith J, Petersen CM, Cullen PJ, Klumpperman J, Geuze H. SNX1 defines an early endosomal recycling exit for sortilin and mannose 6-phosphate receptors. Traffic. 2008;9:580–93.

229. Seaman MNJ. The Retromer Complex: From Genesis to Revelations. Trends Biochem Sci. 2021;46:608–20.

230. Yang M, Lim Y, Li X, Zhong JH, Zhou XF. Precursor of brain-derived neurotrophic factor (proBDNF) forms a complex with Huntingtin-associated protein-1 (HAP1) and sortilin that modulates proBDNF trafficking, degradation, and processing. J Biol Chem. 2011;286:16272–84.

231. Walter J, Fluh rer R, Hartung B, Willem M, Kaether C, Capell A, Lammich S, Multhaup G, Haas C. Phosphorylation regulates intracellular trafficking of beta-secretase. J Biol Chem. 2001;276:14634–41.

232. Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal degradation, and processing. J Biol Chem. 2011;286:16272–84.

233. Tesco G, Koh YH, Kang EL, Cameron AN, Das S, Sena-Esteves M, Hiltunen Tiveron C, Fasulo L, Capsoni S, Asaro A, Sinha R, Bakun M, Kalnytska O, Carlo-Spiewok AS, Rubel T, Mortensen MB, Kjolby M, Gunnersen S, Larsen JV, Palmfeldt J, Falk E, Nykjaer A, Bentzon JF. Targeting sortilin in immune cells reduces proinflammatory cytokines and atherosclerosis. J Clin Investig. 2014;124:5317–22.

234. Scott SA, Mufson EJ, Weingartner JA, Skau KA, Crutcher KA. Nerve growth factor in Alzheimer’s disease: increased levels throughout the brain coupled with declines in nucleus basalis. J Neu rosci. 1995;15:6213–21.

235. Capsoni S, Tiveron C, Amato G, Vignone D, Cattaneo A. Peripheral neutralization of nerve growth factor induces immunosuppressive and central neurodegeneration in transgenic mice. J Alzheimer’s Dis. 2010;20:527–46.

236. Tiveron C, Fasulo L, Capsoni S, Malerba F, Marinelli S, Paoloetti F, Piccinin S, Scardigli R, Amato G, Brandi R, et al. ProNGF/NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. Cell Death Differ. 2013;20:1017–30.

237. Capsoni S, Amato G, Vignone D, Criscuolo C, Nykjaer A, Cattaneo A. Dissecting the role of sortilin receptor signaling in neurodegeneration induced by NGF deprivation. Biochem Biophys Res Commun. 2013;431:579–85.

238. Capsoni S, Tiveron C, Vignone D, Amato G, Cattaneo A. Dissociating the involvement of tropomyosin-related kinase A and p75 neurotrophin receptor signaling in NGF deficit-induced neurodegeneration. Proc Natl Acad Sci USA. 2010;107:12299–304.

239. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nat Med. 2004;10(Suppl):S10-17.

240. Castle AR, Gill AC. Physiological Functions of the Cellular Prion Protein. Front Mol Biosci. 2017;4:19.

241. Chen RJ, Chang WW, Lin YC, Cheng PL, Chen YR. Alzheimer’s amyloid-beta oligomers rescue cellular prion protein induced tau reduction via the Fyn pathway. ACS Chem Neurosci. 2013;4:1287–96.

242. Griffiths HH, Whitehouse IU, Baybutt H, Brown D, Kellett KA, Jackson CD, Turner AJ, Picardo P, Manson JC, Hooper NM. Prion protein interacts with BACE1 protein and differentially regulates its activity toward wild type and Swedish mutant amyloid precursor protein. J Biol Chem. 2011;286:399–500.

243. Whitehouse IU, Miners JS, Glenmon EB, Kehoe PG, Love S, Kellett KA, Hooper NM. Prion protein is decreased in Alzheimer’s brain and inversely correlates with BACE1 activity, amyloid-beta levels and Braak stage. PLoS ONE. 2013;8:e59554.

244. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, Baybutt HH, Turner AJ, Hooper NM. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer’s amyloid precursor protein. Proc Natl Acad Sci USA. 2007;104:11062–7.

245. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, Strittmatter SM. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci. 2010;30:6367–74.

246. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009;457:1128–32.

247. Purro SA, Nicol AI, Collinge J. Prion Protein as a Toxic Acceptor of Amyloid-beta Oligomers. Biol Psychiatry. 2018;83:358–68.
260. Salazar SV, Gallardo C, Kaufman AC, Herber CS, Haas LT, Robinson S, Manson JC, Lee MK, Strittmatter SM. Conditional Deletion of Pmp22 Rescues Behavioral and Synaptic Deficits after Disease Onset in Transgenic Alzheimer's Disease. J Neurosci. 2013;37:9207–21.

261. Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schluter H, Hildebrand D, Zerr I, Matschke J, Glätzel M. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer's disease. Brain. 2014;137:833–86.

262. Um JW, Kaufman AC, Kostylev MA, Heiss JK, Stagi M, Takahashi H, Kerrick ME, Vortmeyer A, Wisniewski T, Koleske AJ, et al. Metabotropic glutamate receptors are a coscoreceptor for Alzheimer's aβ oligomer bound to cellular prion protein. Neuron. 2013;79:887–902.

263. Haas LT, Kostylev MA, Strittmatter SM. Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5). J Biol Chem. 2014;289:24680–77.

264. Panes JD, Saavedra P, Pineda B, Escobor K, Cuevas ME, Moraga-Cid G, Fuentealba J, Rivais C, Rezaei H, Muñoz-Montesino C, Pöhl C (as a Transducer of Physiological and Pathological Signals. Front Mol Neurosci. 2021;14:762918.

265. Takahashi RH, Yokotsuka M, Tobiume M, Sato Y, Hasegawa H, Nagao T, Gouras GK. Accumulation of cellular prion protein within β-amyloid oligomer plaques in aged human brains. Brain Pathol (Zurich, Switzerland). 2021;31:1329–31.

266. Brody AH, Strittmatter SM. Synaptotoxic Signaling by Amyloid Beta Oligomer assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer's disease. Brain. 2014;137:833–86.

267. Ariga M, Nedachi T, Katagiri H, Kanzaki M. Functional role of sortilin in myogenesis and development of insulin-responsive glucose transport system in C2C12 myocytes. J Biol Chem. 2006;281:10208–20.

268. Uchiyama K, Tomita M, Yano M, Chida J, Hara H, Das NR, Nykjaer A, Virgilio E, De Marchi F, Contaldi E, Dianzani U, Cantello R, Mazzini L, Wang XM, Zeng P, Fang YY, Zhang T, Tian Q. Progranulin in neurodegenerative disease. J Neurosci. 2017;37:9207–21.

269. Mohagheghi F, Prudencio M, Stuani C, Cook C, Jansen-West K, Dickson DW, Petrucelli L, Buratti E. TDP-43 functions within a network of hnRNP receptors. Proc Natl Acad Sci USA. 2012;109:21510–5.

270. Li J, Matye DJ, Wang Y, Li T. Sortilin 1 knockout alters basal adipose glucose metabolism but not diet-induced obesity in mice. FEBS Lett. 2017;591:1018–28.

271. Karasov H, Melander O, Guiducci C, Sarti A, Burtt NP, Riedel M, Cooper GM, Roos C, Voight BF, Hauvillinä AS, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40:189–97.

272. Madsen P, Jansen P, Heeren J, Willnow TE, Nykjaer A. Sort1, encoded by SORCS1, localized in somata and dendrites of neurons throughout the murine CNS. PLoS One. 2012;7:e44670.

273. Tanaka MH, Ohtsuka T, Kusumoto R, Hashimoto T, Kobayashi T, Tanaka T, Hara H. E. Transcriptional control of intestinal cholesterol absorption, adipose tissue hormone production, and energy expenditure by Sortilin. Sci Rep. 2018;8:9006.

274. Lui A, Sparks R, Patel R, Patel NA. Identification of Sortilin Alternatively Spliced Variants in Mouse 3T3L1 Adipocytes. Int J Mol Sci. 2021;22:983.

275. Kjolby M, Andersen OM, Breiderhoff T, Fjorback AW, Pedersen KM, Geerlings M, Borgmeyer I. SorCS1, a member of the novel sorting receptor family, is expressed in neurons throughout the brain and peripheral tissues. J Neurochem. 2010;115:1804–18.

276. Strandbygaard D, Moeller A, Petersen CM, Thirup SS. Acidic pH polarization required for synaptic function. PLoS Biol. 2019;17:e3000466.

277. Sendtner M, Jensen-Bohr I, Vonscek MA, Skarda R, Kleeberger S, Gravel S, et al. Targeting of neuronal Sort1 facilitates PCSK9 secretion. Cell Metab. 2014;19:310–8.

278. Nakamura K, Kato Y, Nishiyama K, Ohtani T, Ishii T, Sato H, Nakano F, Nakada T, Takahashi SJ. Glucose deprivation attenuates sortilin levels in skeletal muscle cells. Endocr J. 2017;64:255–68.

279. Li J, Matye DJ, Li T. Insulin resistance induces posttranslational sorting of sortilin 1 in degradation in mice. J Biol Chem. 2015;290:11526–36.

280. Lin BY, Pich PF, Kandor KD. Sortilin is a major protein component of Glut4-containing vesicles. J Biol Chem. 1997;272:24145–7.

281. Chen C, Li J, Matye DJ, Wang Y, Li T. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice. J Lipid Res. 2019;60:539–49.

282. Rabinowich L, Fishman S, Hubel E, Thurm T, Park WJ, Pewzner-Jung Y, Soroa A, Erez N, Halpern Z, Futereman A, Ziv-Hiller I. Sortilin deficiency improves the metabolic phenotype and reduces hepatic steatosis of mice subjected to diet-induced obesity. J Hepatol. 2015;62:175–81.

283. Hartig S, Rogers MA, Pham T, Wen JR, Miyarchik AK, Aiikawa M, Aiikawa E. Transcriptional control of intestinal cholesterol absorption, adipose tissue hormone production, and energy expenditure by Sortilin. Sci Rep. 2018;8:9006.

284. Ariga M, Yoneyama F, Tsuchiya Y, Ishii T, Sato H, Hakuno F, Nedachi T, Takahashi SJ. Glucose deprivation attenuates sortilin levels in skeletal muscle cells. Endocr J. 2017;64:255–68.

285. Sliwa KD, Vorbrodt M, Kaiser T, Fuhrer M, Kristof J, Bieri JG, et al. Rescue of Transgenic Alzheimer's Pathophysiology by Polymeric Cellular Prion Protein Receptor Antagonists. Cell. 2019;176:1368.

286. Uchiyama K, Tomita M, Yano M, Chida J, Hara H, Das NR, Nykjaer A, Sakaguchi S. Prions amplify through degradation of the VPS10P sorting receptor sortilin. PLoS Pathog. 2017;13:e1006470.
Environment Induces Dimerization and Ligand Binding Site Collapse in the Vps10p Domain of Sortilin. Structure (London, England). 1993;1(7):1809–1819.e1803.

304. Lansen JV, Hermey G, Sorensen ES, Prabakaran T, Christensen EI, Gilemamy J, Madsen P, Petersen CM. Human sorCS1 binds sortilin and hampers its cellular functions. Biochem J. 2014;457:277–88.

305. Sanders TH, Weiss J, Hogewood L, Chen L, Paton C, McMahlan RL, Sweett JD. Cognition-Enhancing Vagus Nerve Stimulation Alters the Epigenetic Landscape. J Neurosci. 2019;39:3454–69.

306. Riecz C, Lee JH, Rogers RS, Mayeux R. Impact of genetic variation in SORCS1 on memory retention. PLoS ONE. 2011;6:e24588.

316. Vieira MNN, Lima-Filho RAS, De Felice FG. Connecting Alzheimer’s disease on chromosome 10. Hum Mutat. 2009;30:463–71.

319. Kebede MA, Oler AT, Gregg T, Balloin AJ, Johnson A, Mitok K, Rabaglia M, Schueler K, Stapleton D, Thorstenson C, et al. SORCS1 is necessary for normal insulin secretory granule biogenesis in metabolically stressed beta cells. J Clin Investig. 2014;124:4240–56.

323. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7:45–61.

324. Michailidis M, Morantou D, Tata DA, Kalinderi K, Papamitsou T, Papaligkas A V. Alzheimer’s Disease as Type 3 Diabetes: Common Pathophysiological Mechanisms Between Alzheimer’s Disease and Type 2 Diabetes. Int J Mol Sci. 2022;23:2687.

327. Clee SM, Yandell BS, Schueler K, Rabaglia ME, Richards OC, Raines SM, Kabara EA, Klass DM, Mun ET, Stapleton DS, et al. Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet. 2006;38:688–93.

329. Paterson AD, Wattcott D, Boriq AI, Hosseini SM, Yandell BS, Blangero J, Hsuhe WA, et al. SORCS1: a novel human type 2 diabetes susceptibility gene suggested by the mouse. Diabetes. 2007;56:1922–9.

331. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer’s disease. J Alzheimers Dis. 2005;7:45–61.

332. Lahiri DK, Maloney B. The LEARn* (latent early-life associated regulation) model: an epigenetic pathway linking metabolic and cognitive disorders. J Alzheimers Dis. 2012;20:513–50.

333. Duits FH, Brinkmali G, Teunissen CE, Brinkmali A, Scheltens P, Van der Ven A, Njolstad PR. Evaluation of four novel genetic variants affecting hemoglobin A1c levels in a population-based type 2 diabetes cohort (the HUNT2 study). BMC Med Genet. 2011;12:20.

334. Cataldo A, Rebeck GW, Heter JF, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C, Collinge J, Lloyd SE. In vitro screen of prion disease susceptibility genes using the scrapie cell assay. Hum Mol Genet. 2014;23:5102–8.

335. de la Monte SM, Wands JR, Kim H, Khrystynia A, Patel S, Sheehan L, Greenberg DS, et al. A genome-wide association study identifies a novel major locus for glycemic control in type 1 diabetes, as measured by both A1C and glucose. Diabetes. 2010;59:539–49.

336. Cataldo A, Rebeck GW, Heter JF, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C, Collinge J, Lloyd SE. In vitro screen of prion disease susceptibility genes using the scrapie cell assay. Hum Mol Genet. 2014;23:5102–8.

337. Brito-Moreira J, Lourenco MV, Oliveira MM, Ribeiro FC, Ledo JH, Diniz LP, et al. Interaction of amyloid-beta with GABAAergic transmission caused by Alzheimer’s disease-associated Abeta oligomers with neuron-intrinsic and neuron-intrinsic 1 mediates synapse damage and memory loss in mice. J Biol Chem. 2017;292:7327–37.

338. Naito Y, Tanabe Y, Lee AK, Hamel E, Takahashi H. Amyloid-beta Oligomers Interact with Neurexin and Diminish Neurexin-mediated Excitatory Presynaptic Organization. Sci Rep. 2017;7:42548.

339. Sindhi IA, Tannenberg RK, Dodd PR. Role for the neurexin-neulinoid complex in Alzheimer’s disease. Neurobiol Aging. 2014;35:746–56.

340. Kreis A, Desloovere J, Suelves N, Pierrot N, Yema I, Issa F, Schakman O, Guaralini R, de Clippele M, Tajeddine N, et al. Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission. Sci Rep. 2021;11:17600.
342. Henley JM, Wilkinson KA. Synaptic AMPA receptor composition in development, plasticity and disease. Nat Rev Neurosci. 2016;17:337–50.

343. Boggiud S, Molgaard S, Gerup S, Nyegaard JR. Highly segregated localization of the functionally related vps10 receptors sortilin and SorCS2 during neurodevelopment. J Comp Neurol. 2019;528(8):1267–86.

344. Ma Q, Yang J, Milner TA, Vonsattel JG, Falco ME, Tesslerollo L, Hempstead BL. SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's disease. JCI insight. 2017;2:e98995.

345. Malik AR, Szydlowska K, Nizinska K, Asaro A, van Vliet EA, Dittmar G, Fritsche-Guenter R, Kirvan JN, Nykaera A, et al. SorCS2 Controls Functional Expression of Amino Acid Transporter EAAT3 and Protects Neurons from Oxidative Stress and Epilepsy-Induced Pathology. Cell Rep. 2019;26:2792–2804.e2796.

346. Yang J, Ma Q, Dincheva I, Giza J, Jing D, Marinic T, Milner TA, Rajadhyaksha A, Lee FS, Hempstead BL. SorCS2 is required for social memory and trafficking of the NMDA receptor. Mol Psychiatry. 2021;26:927–40.

347. Gospodinova KO, Olsen D, Kaas M, Anderson SM, Phillips J, Walker RM, Bermingham ML, Payne AL, Giannopoulos P, Pandya O, Spiers-Iones TL, Abbott CM, Porteous DJ, Gerup S, Evans KL. Loss of SorCS2 is Associated with Neuropathological Double Strand Breaks. Cell Mol Neurobiol. 2021. https://doi.org/10.1007/s10571-021-01163-7.

348. Chaves G, Stanley J, Pourmand N. Mutant Huntingtin Affects Diabetes and Alzheimer's Markers in Human and Cell Models of Huntington's Disease. Cells. 2019;8:962.

349. Bothwell M, Giniger E. Alzheimer's disease: neurodevelopment converges with neurodegeneration. Cell. 2000;102:271–3.

350. Batool S, Raza H, Jiaing D, Marinic T, Milner TA, Rajadhyaksha A, Lee FS, Hempstead BL. SorCS2 is required for social memory and trafficking of the NMDA receptor. Mol Psychiatry. 2021;26:927–40.

351. Olsen D, Wellner N, Kaas M, de Jong IEM, Sotty F, Didriksen M, Glerup S, Vignoli B, Sansevero G, Sasi M, Rimondini R, Blum R, Bonaldo V, Biasini M, Mizui T, Ishikawa Y, Kumanogoh H, Lume M, Matsumoto T, Hara N, Breiderhoff T, Christiansen GB, Pallesen LT, Vaegter C, Nykjaer A, Holm MM. The sorting receptor SorCS3 is a stronger regulator of glutamate receptor trafficking compared to SorCS2. EMBO Rep. 2019;26:2792–2804.e2796.

352. Christiansen GB, Andersen KH, Riis S, Nykjaer A, Bolcho U, Jensen MS, Holm MM. The sorting receptor SorCS3 is a stronger regulator of glutamate receptor trafficking compared to SorCS2. EMBO Rep. 2019;26:2792–2804.e2796.

353. Li B, Gao Y, Zhang W, Xu JR. Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of Alzheimer disease. J Neurosci Res. 2018;96:828–40.

354. Wu CC, Lien CC, Hou WH, Chang PM, Tsai KJ. Gain of BDNF Function in Engrafted Neural Stem Cells Promotes the Therapeutic Potential for Alzheimer's Disease. Sci Rep. 2016;6:27358.

355. Choi SH, Bylykbashi E, Chatila ZK, Lee SW, Pulli B, Clemenson GD, Kim E, Rompala A, Oram MK, Asselin C, et al. Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer's mouse model. Science (New York, NY). 2018;361 eaar8821.

356. de Pins B, Cifuentes-Diaz C, Thalima Farah A, Lopez-Molina L, Montalban E, Sancho-Balsells A, Lopez A, Gines S, Delgado-Garcia JM, Alberch J, et al. Conditional BDNF delivery from astrocytes rescues memory deficits, spine density and synaptic properties in the 5xFAD mouse model of Alzheimer disease. J Neurosci. 2019;39(13):2441–58.

357. Lee WC, Almeida S, Prudencio M, Gauffield TR, Zhang YJ, Tay WA, Bauer PO, Chew J, Sasaguri H, Jansen-West KR, et al. Targeted manipulation of the sortilin-progranulin axis rescues progranulin haplosufficiency. Hum Mol Genet. 2014;23:1647–78.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.